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A B S T R A C T
Background
Ulcerative colitis is an inflammatory condition aMecting the colon, with an annual incidence of approximately 10 to 20 per 100,000
people. The majority of people with ulcerative colitis can be put into remission, leaving a group who do not respond to first- or second-
line therapies. There is a significant proportion of people who experience adverse eMects with current therapies. Consequently, new
alternatives for the treatment of ulcerative colitis are constantly being sought. Probiotics are live microbial feed supplements that
may beneficially aMect the host by improving intestinal microbial balance, enhancing gut barrier function and improving local immune
response.
Objectives
The primary objective was to determine the eMicacy of probiotics compared to placebo, no treatment, or any other intervention for
the maintenance of remission in people with ulcerative colitis. The secondary objective was to assess the occurrence of adverse events
associated with the use of probiotics.
Search methods
We searched CENTRAL, MEDLINE, Embase, and two other databases on 31 October 2019. We contacted authors of relevant studies and
manufacturers of probiotics regarding ongoing or unpublished trials that may be relevant to the review, and we searched ClinicalTrials.gov.
We also searched references of trials for any additional trials.
Selection criteria
Randomised controlled trials (RCTs) that compared probiotics against placebo or any other intervention, in both adults and children, for
the maintenance of remission in ulcerative colitis were eligible for inclusion. Maintenance therapy had to be for a minimum of three months
when remission has been established by any clinical, endoscopic,histological or radiological relapse as defined by study authors.
Data collection and analysis
Two review authors independently conducted data extraction and 'Risk of bias' assessment of included studies. We analysed data using
Review Manager 5. We expressed dichotomous and continuous outcomes as risk ratios (RRs) and mean diMerences (MDs) with 95%
confidence intervals (CIs). We assessed the certainty of the evidence using the GRADE methodology.
Main results
In this review, we included 12 studies (1473 randomised participants) that met the inclusion criteria. Participants were mostly adults. The
studies compared probiotics to placebo, probiotics to 5-aminosalicylic acid (5-ASA) and a combination of probiotics and 5-ASA to 5-ASA.
The studies ranged in length from 12 to 52 weeks. The average age of participants was between 32 and 51, with a range between 18 and
88 years. Seven studies investigated a single bacterial strain, and five studies considered mixed preparations of multiple strains. The risk
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of bias was high in all except three studies due to selective reporting, incomplete outcome data and lack of blinding. This resulted in low-
to very low-certainty of evidence.
It is uncertain if there is any diMerence in occurrence of clinical relapse when probiotics are compared with placebo (RR 0.87, 95% CI 0.63
to 1.18; 4 studies, 361 participants; very low-certainty evidence (downgraded for risk of bias, imbalance in baseline characteristics and
imprecision)). It is also uncertain whether probiotics lead to a diMerence in the number of people who maintain clinical remission compared
with placebo (RR 1.16, 95% CI 0.98 to 1.37; 2 studies, 141 participants; very low-certainty evidence (downgraded for risk of bias, imbalance
in baseline characteristics and imprecision)).
When probiotics are compared with 5-ASA, there may be little or no diMerence in clinical relapse (RR 1.01, 95% CI 0.84 to 1.22; 2 studies,
452 participants; low-certainty evidence) and maintenance of clinical remission (RR 1.06, 95% CI 0.90 to 1.25; 1 study, 125 participants;
low-certainty evidence). It is uncertain if there is any diMerence in clinical relapse when probiotics, combined with 5-ASA are compared
with 5-ASA alone (RR 1.11, 95% CI 0.66 to 1.87; 2 studies, 242 participants; very low-certainty evidence (downgraded due to risk of bias and
imprecision)). There may be little or no diMerence in maintenance of remission when probiotics, combined with 5-ASA, are compared with
5-ASA alone (RR 1.05, 95% CI 0.89 to 1.24; 1 study, 122 participants; low-certainty evidence).
Where reported, most of the studies which compared probiotics with placebo recorded no serious adverse events or withdrawals due to
adverse events. For the comparison of probiotics and 5-ASA, one trial reported 11/110 withdrawals due to adverse events with probiotics
and 11/112 with 5-ASA (RR 1.02, 95% CI 0.46 to 2.25; 222 participants; very low-certainty evidence). Discontinuation of therapy was due
to gastrointestinal symptoms. One study (24 participants) comparing probiotics combined with 5-ASA with 5-ASA alone, reported no
withdrawals due to adverse events; and two studies reported two withdrawals in the probiotic arm, due to avascular necrosis of bilateral
femoral head and pulmonary thromboembolism (RR 5.29, 95% CI 0.26 to 107.63; 127 participants; very low-certainty evidence).
Health-related quality of life and need for additional therapy were reported infrequently.
Authors' conclusions
The eMectiveness of probiotics for the maintenance of remission in ulcerative colitis remains unclear. This is due to low- to very low-
certainty evidence from poorly conducted studies, which contribute limited amounts of data from a small number of participants. Future
trials comparing probiotics with 5-ASA rather than placebo will better reflect conventional care given to people with ulcerative colitis.
Appropriately powered studies with a minimum length of 12 months are needed.
P L A I N   L A N G U A G E   S U M M A R Y
Probiotics for maintenance of remission in ulcerative colitis
What is the aim of this review?
The aim of this Cochrane Review was to find out whether probiotics can maintain remission in people with ulcerative colitis. We collected
and analysed data from 12 studies with a total of 1473 people to answer this question.
Key messages
The question on whether probiotics can maintain remission in people with ulcerative colitis remains unanswered. There were no serious
adverse events when probiotics were compared with placebo. However, one study reported similar numbers of serious adverse events in
people who had probiotics and those who received 5-aminosalicylic acid (5-ASA, an anti-inflammatory medicine used to treat ulcerative
colitis and other conditions. . More information as to what these serious adverse events are, was not provided.
What was studied in the review?
Ulcerative colitis is a chronic disease of the large bowel, which causes inflammation (swelling). Some of the symptoms include tummy
pain, diarrhoea and tiredness. Probiotics are living microscopic organisms that are thought to change the growth of bacteria in the bowel
and reduce inflammation.
What are the main results of the review?
We searched for randomised controlled trials (RCTs; clinical studies where people are randomly put into one of two or more treatment
groups) comparing probiotics with placebo (dummy treatment), probiotics with 5-ASA and a combination of probiotics and 5-ASA with 5-
ASA. There were 12 RCTs involving 1473 participants. The trials looked at adult males and females. Only three studies clearly stated that
participants were not allowed to take other medication outside of those being compared.
1) There was no clear diMerence in the number of people who had a clinical relapse when probiotics were compared with placebo.
2) There was also no clear diMerence in the number of people who had a clinical relapse when probiotics were compared with 5-ASA.
Probiotics for maintenance of remission in ulcerative colitis (Review)









Cochrane Database of Systematic Reviews
3) It is uncertain whether probiotics lead to a diMerence in the number of people who remain in clinical remission compared with placebo
because the quality of evidence is very low.
4) There was no clear diMerence in the number of people who remained in clinical remission when probiotics were compared to 5-ASA.
5) When probiotics combined with 5-ASA was compared to 5-ASA alone, there was no clear diMerence in the number of people who
remained in clinical remission.
6) It is uncertain whether probiotics combined with 5-ASA lead to a diMerence in the number of people who have a clinical relapse when
compared with 5-ASA alone.
7) No serious adverse events were reported in the trials which compared probiotics with placebo. One study which compared
probiotics with 5-ASA reported similar numbers of serious adverse events with both treatments. Discontinuation of therapy was due to
gastrointestinal disorders, such as bloody stools, nausea, diarrhoea and abdominal pain.
8) There was not enough information from the studies on how probiotics aMect people's quality of life and the need for additional therapy
when compared to other treatments.
Conclusion
We are uncertain as to whether probiotics can maintain remission in people with ulcerative colitis. This is because the studies had very few
participants and were not conducted using reliable methods. With the evidence presented in these studies, we are unable to make strong
conclusions into the eMectiveness of probiotics; better designed studies with more participants are needed.
How up-to-date is this review?
This review is up-to-date as of October 2019.
Probiotics for maintenance of remission in ulcerative colitis (Review)








































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Probiotics compared to placebo for maintenance of remission in ulcerative colitis
Probiotics compared to placebo for maintenance of remission in ulcerative colitis






























Clinical relapse was defined as a flare-up
(NCT02361957), CAI ≤ 5 (Yasushi 2015) and persistence
of a rectal bleeding score of ≤ 2 on Sutherland DAI
score for 3 consecutive days and/or initiation of remis-
sion induction therapy for worsening of ulcerative col-
itis (Matsuoka 2018), respectively
Study populationMaintenance of clinical
remission
(52 weeks)








Maintenance of remission is the number of partici-
pants who did not relapse. One additional study re-
ported insufficient data for inclusion in the meta-
analysis, therefore, we did not further analyse the re-
sults (reported P = 0.643).
Serious adverse events
(48 to 52 weeks)
See comment See comment - 351
(4 RCTs)
- Four studies reported that no serious adverse events
occurred.
Withdrawal due to ad-
verse events
See comment See comment - 113
(2 RCTs)























































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its
95% CI).
CAI: colitis activity index CI: confidence interval; DAI: disease activity index; IBD-Q: inflammatory bowel disease questionnaire; MD: mean difference; RCT: randomised con-
trolled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded three times: risk of reporting bias and other bias due to imbalance in baseline characteristics, imprecision due to small sample size.
bDowngraded two times: imprecision due to small sample size from a single study resulting in wide confidence interval.
 
 
Summary of findings 2.   Probiotics compared to 5-aminosalicylic acid (5-ASA) (mesalazine) for maintenance of remission in ulcerative colitis
Probiotics compared to 5-ASA (mesalazine) for maintenance of remission in ulcerative colitis





























Clinical relapse was based on the presence of all the
following: CAI > 6 (or an increase in CAI of at least
3 points with CAI = 4 being exceeded at the same
time); endoscopic index > 4; histological signs of
acute inflammation (Kruis 2004) and appearance of
ulcerative colitis symptoms or an increase in CAI to
more than 4 points (Zocco 2006)
Study populationMaintenance of clini-
cal remission
(52 weeks)







Maintenance of remission is the number of partici-














































































































































Serious adverse events were not reported in detail
Study populationWithdrawal due to
adverse events
(52 weeks)








Discontinuation of therapy was due to gastrointesti-
nal disorders, such as bloody stools, nausea, diar-
rhoea, mucous secretion and abdominal pain
Need for additional
therapy








MD 0.80 points low-






Scale: IBD-Q, range 1 -32, higher score = better quali-
ty of life
*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its
95% CI).
5-ASA: 5-aminosalicylic acid; CAI: colitis activity index CI: confidence interval; IBD-Q: inflammatory bowel disease questionnaire; RCT: randomised controlled trial; RR: risk
ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded two times: risk of attrition bias and other bias due to imbalance in baseline characteristics, imprecision due to sample size not meeting the optimal information size.
bDowngraded two times: risk of performance and detection bias from an open-label study and small number of events.
cDowngraded two times: risk of attrition bias and imprecision due to small sample size.
dDowngraded three times: risk of attrition bias, imprecision due to small number of events from a single study resulting in wide confidence interval which includes appreciable
harm. Serious adverse events were not described in detail.eDowngraded three times: risk of attrition bias, imprecision due to small number of events from a single study resulting




































































































































Summary of findings 3.   Probiotic + 5-aminosalicylic acid (5-ASA) (mesalazine) compared to 5-ASA (mesalazine) for maintenance of remission in
ulcerative colitis
Probiotic + 5-ASA (mesalazine) compared to 5-ASA (mesalazine) for maintenance of remission in ulcerative colitis
Patient or population: people with ulcerative colitis in remission
Setting: hospitals




























Clinical relapse was defined as CAI > 4 (Kruis
1997) and appearance of ulcerative colitis symp-
toms or an increase in CAI to more than 4 points
(Zocco 2006).
Study populationMaintenance of clinical re-
mission
(24 to 52 weeks)








Maintenance of clinical remission is the number
of participants who did not relapse.
Serious adverse events Not reported in any of the studies
Study populationWithdrawal due to adverse
events
(12 to 52 weeks)








Two discontinuations in the probiotic arm were
due to avascular necrosis of bilateral femoral
head and pulmonary thromboembolism.
One study (n = 24) reported no events in either
arm.
Need for additional therapy Not reported in any of the studies
Health-related quality of life Not reported in any of the studies
*The risk in the intervention group (and its 95% confidence interval) is based on the mean risk in the comparison group and the relative effect of the intervention (and its
95% CI).
5-ASA: 5-aminosalicylic acid; CAI: Colitis activity index CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio


































































































































High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded three times: risk of attrition bias, imprecision due to small number of events and confidence interval which includes appreciable harm.
bDowngraded two times: risk of performance and detection bias from an open-label study, imprecision due to small number of events.
cDowngraded three times: unclear risk of selection bias (lack of information on sequence generation), imprecision due to small number of events in a single study and confidence
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B A C K G R O U N D
Description of the condition
Ulcerative colitis is a chronic relapsing disease, with the greatest
reported incidence in mainland Europe and Scandinavia of 9.2
to 20.3 per 100,000 people (LoTus 2004), totalling approximately
2.2 million suMerers in Europe alone. The peak incidence of the
disease occurs between 15 and 25 years of age, and there is another
smaller prevalence at ages 55 to 65. The disease is characterised
by abdominal pain, bloody diarrhoea and faecal urgency. The
diagnosis of ulcerative colitis is based on medical history, signs and
symptoms, and any endoscopic or histopathological findings.
The disease is caused by diMuse inflammation, which starts at
the rectum, spreads proximally, and is limited to the colon. The
aetiology behind the disease is unknown, but is likely to be
multifactorial; consisting of a genetic predisposition, dysregulation
of the mucosal and epithelial barrier and lastly dysbiosis, although
whether dysbiosis causes or is a result of the disease remains
unclear (Ungaro 2016). The genetic component was further
evaluated by Cleynen 2016 and a strong association between HLA
DRB1 and ulcerative colitis was found. The genetic predisposition
creates a four-fold risk for first-degree relatives.
Description of the intervention
Probiotics are live micro-organisms, that when consumed, may
provide multiple health benefits. They produce their benefits by
altering the gut microbiome through either enhancing the activity,
volume or both, of the normal flora. Lactobacillus spp, for example,
is one of the more popular probiotics and is thought to secrete
bacteriocin, blocking the adherence of translocation of harmful
bacteria (Panigrahi 2014).
Lactobacillus rhamnosus GG (L rhamnosus) produced mixed
responses in animal models of colitis (Dieleman 2003; Shibolet
2002), as did Lactobacillus plantarum (L plantarum) 299V
(Dieleman 2003; Kennedy 2000; Schultz 2002). Studies investigating
combinations of probiotic species incorporated within VSL#3 have
demonstrated a partial reduction of colitis in animal models
(Madsen 2001; Shibolet 2002). There has been increasing interest
in the use of probiotics, as they are considered safe and easily
accessible (Ong 2019). It is worth noting that there are a huge
number of diMerent preparations available, varying in the specific
strains isolated, the use of mixed strains in a single preparation,
the form of the preparation and finally the licensing arrangements
surrounding the preparations (medicinal versus food products).
How the intervention might work
There is growing evidence looking at the eMects of probiotics in
the use of inducing remission in ulcerative colitis since a previous
Cochrane review (Mallon 2007). Due to the part that dysbiosis plays
in ulcerative colitis, there is potential benefit in trying to restore
the endogenous flora. Several observations, both on humans
and animal models, emphasised the importance of bacterial
flora in inflammatory bowel disease pathogenesis, justifying the
current interest in antibiotic and probiotic therapies aimed at
the manipulation of enteric flora (Cui 2004). The therapeutic
eMicacy of probiotics has been demonstrated in various models
of experimental colitis, including interleukin-10 deficient mice
(Madsen 1999; Schultz 2002), and acetic acid-induced colitis in rats
(Fabia 1993).
Why it is important to do this review
In the UK, National Institute for Health and Care Excellence (NICE)
and USA guidelines state that first-line therapy for maintenance
of remission in ulcerative colitis is 5-aminosalicylic acid (5-ASA)
(NICE 2019). 5-ASA works by binding to PPAR-# and reducing
cytokine production. Some of the adverse eMects associated with
5-ASA include headache, rash, nausea (common), pancreatitis
(uncommon), and agranulocytosis (rare). Due to these side eMects,
some people are unable to tolerate the drug. If 5-ASA fails
to work then other therapies to maintain remission include
immune suppressants, such as anti-tumour necrosis factor (TNF)
monoclonals, vedolizumab and tofacitinib may be used . These
drugs work by blocking leukocyte recruitment at the molecular
and vascular level (Fiorino 2016), some of the side eMects include
headache, dizziness and arthralgia.
The relapsing and remitting nature of the disease means that
people can be in and out of hospital, experimenting with diMerent
drug regimes. The treatment costs Europe between GBP 11 to 26
billion pounds annually, with per patient costs approximately GBP
8011 to 9306 (Cohen 2010). If an alternative, cheaper treatment can
be found for ulcerative colitis, then it would greatly benefit not only
a budget stricken National Health Service (NHS), but also improve
patients' quality of life. Whilst some studies have suggested that
probiotics may be useful for maintenance of remission in mild
to moderate ulcerative colitis (Kruis 2004; Zocco 2006), others
have failed to show any benefit (Kruis 1997; Rembacken 1999). In
this review we investigate the available evidence on the use of
probiotics for the maintenance of remission in ulcerative colitis.
O B J E C T I V E S
The primary objective was to determine the eMicacy of probiotics
compared to placebo, no treatment, or any other intervention for
the maintenance of remission in people with ulcerative colitis. The
secondary objective was to assess the occurrence of adverse events
associated with the use of probiotics.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomised controlled trials (RCTs), with a
minimum duration of three months, for inclusion in the review.
Types of participants
People of any age with ulcerative colitis in remission, defined as
clinical, endoscopic, histological or radiological relapse by study
authors.
Types of interventions
Probiotics administered in any form (drink, powder, capsule), orally
as a single species, or as a cocktail of multiple species compared to
no treatment, placebo or any other intervention.
Types of outcome measures
Primary outcomes
• Relapse (clinical, endoscopic, histopathological or radiological),
as defined by the authors of the primary studies.
Probiotics for maintenance of remission in ulcerative colitis (Review)
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Where studies reported on the number of participants who did not
experience a relapse, i.e. those who remained in remission, this was
noted under 'maintenance of clinical remission'.
Secondary outcomes
• Serious adverse events
• Withdrawal due to adverse events
• Need for additional therapy
• Health-related quality of life, as measured by a validated quality
of life tool
Search methods for identification of studies
Electronic searches
We conducted a comprehensive and systematic search to identify
RCTs from inception to 31 October 2019 using the following
databases.
• Cochrane Inflammatory Bowel Disease (IBD) Specialized Trials
Register




We did not place any restrictions on publication dates (aTer 1966)
or language. See Appendix 1 for the detailed search strategies.
Searching other resources
We inspected the reference lists of all identified studies for more
trials. We also contacted leaders in the field and manufacturers of
probiotics to identify potentially relevant studies. We also searched
ClinicalTrials.gov (clinicaltrials.gov) for ongoing trials (Appendix 1).
Data collection and analysis
We conducted data collection and analysis according to methods
stipulated in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
Selection of studies
We undertook study selection in Covidence. Using the above search
strategy, two review authors (LK, ZIE) identified titles that appeared
to be potentially relevant. These were independently screened and
in circumstances of disagreement, a third review author (AA) was
involved to reach consensus.
There is some evidence that data from abstract publications can
be inconsistent with data from published articles (Pitkin 1999),
therefore we considered abstract publications, but only if suMicient
data were presented to judge inclusion criteria fully and reports
of the primary and secondary outcomes were given. If these were
not available, we contacted authors directly, and if data were not
provided, we excluded such studies.
The review authors, aTer reading the full texts, independently
assessed the eligibility of all trials identified using ad hoc eligibility,
based on the inclusion criteria above. Disagreement among review
authors was again discussed, and agreement was reached by
consensus aTer involvement of a third review author. We contacted
authors of multiple publications, which appeared to report on the
same study, for clarification. A flow chart was included (Figure 1).
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Data extraction and management
We developed a data extraction form and used it to extract
information on relevant features and results of included studies.
Two review authors (LK, ZIE) independently extracted and recorded
data on a predefined checklist. Again, when disagreements
occurred, a third review author (AA) was involved and consensus
was reached. Extracted data included the following items.
• Characteristics of participants: age, sex, disease distribution,
disease duration, disease activity index
• Total number of participants originally assigned to each
intervention group
• Intervention: type and dose of probiotic(s)
• Control: no intervention, placebo or other interventions
• Concurrent medications
• Outcomes: time of assessment, length of follow-up, type
of symptom score used or ulcerative colitis activity index,
definition of remission and relapse, relapse rates, time to
relapse, quality of life assessment, and adverse events
We resolved inconsistencies in data extraction, and transferred
the information above into the Characteristics of included studies
table.
Assessment of risk of bias in included studies
Two review authors (LK, ZIE) independently assessed risk of bias
using the Cochrane 'Risk of bias' tool (Higgins 2011). We assessed
the following domains.
• Selection bias
* Sequence generation (i.e. was the allocation sequence
adequately generated?)
* Allocation sequence concealment (i.e. was allocation
adequately concealed?)
• Performance bias (i.e. was knowledge of the allocated
intervention adequately prevented during the study towards the
participants?)
• Detection bias (i.e. were outcome assessors blinded
adequately?)
• Attrition bias (were attritions and exclusions adequately
reported?)
• Reporting bias: selective outcome reporting (i.e. are reports of
the study free of suggestion of selective outcome reporting?)
• Other potential sources of bias (i.e. was the study apparently free
of other problems that could put it at a high risk of bias?)
We considered subjective outcomes separately in our assessment
of blinding and incompleteness of data. We judged studies to be at
'high', 'low' or 'unclear' risk of bias for each domain assessed. We
judged the risk of bias across studies as follows.
• Low risk of bias (plausible bias unlikely to seriously alter the
results) if all domains are at low risk of bias.
• Unclear risk of bias (plausible bias that raises some doubt about
the results) if one or more domains are at unclear risk of bias.
• High risk of bias (plausible bias that seriously weakens
confidence in the results) if one or more domains are at high risk
of bias.
Disagreements were resolved by consensus. We contacted study
authors when insuMicient information was provided to determine
the risk of bias. Where we obtained information supporting our
judgement on risk of bias through correspondence with study
authors, we indicated this in the 'Risk of bias' table.
Measures of treatment e;ect
The measure of treatment eMect for dichotomous outcomes was
risk ratios (RRs). Where continuous outcomes reported with the
same scale, we used mean diMerences (MDs).
Unit of analysis issues
The unit of analysis was the participant. Where studies assessed
more than two interventions which are relevant to the review, we
made multiple pair wise comparisons and analysed just the groups
of interest. We did not include the same group of participants twice
in the same meta-analysis. We were alert to the unit of analysis
issues relating to outcome reporting at diMerent follow-up times
and only reported outcomes at final follow-up.
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Dealing with missing data
We contacted study authors to request missing data. Where authors
reported both intention-to-treat (ITT) and per protocol analysis,
we preferred the former. However, where ITT analysis was not
conducted or reported in the studies, we regarded withdrawals as
failures. We undertook sensitivity analyses to exclude studies with
missing data. We did not impute missing standard deviations (SDs).
However, we noted any instances where data were extracted from
graphs.
Assessment of heterogeneity
We assessed heterogeneity among trial results by inspection
of graphical presentations and by calculating the Chi2 test of
heterogeneity; we regarded P = 0.10 as statistically significant. We
used the I2 statistic to quantity the eMect of heterogeneity (Higgins
2003).
We based our interpretation of the I2 statistic results on those
suggested by Higgins 2011 (Section 9.5.2):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%; may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We avoided diMerent reporting biases by conducting an extensive
literature search. It was not necessary to generate a funnel plot to
investigate publication bias, as there were an insuMicient number
of studies contributing to the analysis.
Data synthesis
We pooled studies with the same population, intervention,
comparator and outcomes; we did not pool studies which were
clinically heterogenous. We used Review Manager 5 for data
analysis (Review Manager 2014). For dichotomous variables, we
calculated RRs and 95% confidence intervals (CIs) based on a
random-eMects model. For continuous variables, we calculated the
MD and 95% CIs when continuous outcomes were measured using
the same units. We used the fixed-eMect model, as I2 = 0. We had
planned to use the random-eMects model if I2 had been > 0.
Subgroup analysis and investigation of heterogeneity
Had we included a suMicient number of studies, we would have
carried out subgroup analyses based on:
• age (below 18 years and above 18 years); and
• species of probiotic.
Sensitivity analysis
We carried out the following sensitivity analyses, apart from the
exclusion of studies at high risk of bias; this was not possible due to
the paucity of data.
• Only including participants whose outcome is known (i.e.
number of participants who completed the study used as
denominator)
• Study quality (removing those at highest risk of bias)
• Random-eMects versus fixed-eMect models
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE approach to assess the certainty of
evidence related to all outcomes listed in the Types of outcome
measures (Schünemann 2011). The four levels of evidence certainty
are 'high', 'moderate', 'low' or 'very low'. Certainty may be
downgraded due to study limitations (risk of bias), imprecision,
inconsistency, indirectness or publication bias. We derived the
optimal information size for the primary outcomes from the
included studies.
Two review authors (MG, ZIE) independently produced 'Summary
of findings' tables using the GRADEpro GDT soTware for our main
comparisons (GRADEpro GDT 2015). We presented the results for
clinical relapse, maintenance of clinical remission, health-related
quality of life, need for additional therapy, serious adverse events,
and withdrawal due to serious adverse events.
R E S U L T S
Description of studies
Results of the search
The literature search returned 1473 unique records aTer duplicates
were removed; we also identified an additional study from another
source. ATer screening 1474 titles and abstracts, we found 52
studies that met our inclusion criteria. We obtained and screened
the full-text copies of these 52 studies. We included 12 studies
and excluded 30 studies with reasons. We contacted authors of
eight studies for additional information (Bjarnason 2019; Copaci
2014; Shanahan 2006; Wildt 2011; Yasushi 2015; Zocco 2003;
Zocco 2006; NCT02361957); we received responses from three
authors (NCT02361957; Bjarnason 2019; Wildt 2011). We identified
four ongoing studies and six studies are awaiting classification
(Characteristics of ongoing studies; Characteristics of studies
awaiting classification). The results of the search are presented in
the PRISMA flow diagram Figure 1. Full details of the included and
excluded studies are available in the Characteristics of included
studies and Characteristics of excluded studies tables and are
summarised below.
Included studies
Study design and setting
We included 12 studies (Bjarnason 2019; Copaci 2014; Kruis 1997;
Kruis 2004; Matsuoka 2018; NCT02361957; Shanahan 2006; Vejdani
2017; Wildt 2011; Yasushi 2015; Zocco 2003; Zocco 2006). These
studies were either single centre (Bjarnason 2019; Copaci 2014;
NCT02361957; Shanahan 2006; Yasushi 2015; Zocco 2006), or
multicentre (Kruis 1997; Kruis 2004; Matsuoka 2018; Vejdani 2017;
Wildt 2011) parallel group RCTs. The studies were conducted in
hospitals in Italy (Zocco 2003; Zocco 2006), Iran (Vejdani 2017),
Ireland (Shanahan 2006), Japan (Yasushi 2015), the Netherlands
(NCT02361957), Romania (Copaci 2014), the UK (Bjarnason 2019);
multiple centres in Denmark (Wildt 2011) and Japan (Matsuoka
2018); multiple centres across Germany, the Czech Republic,
Austria (Kruis 1997) and Germany, the Czech Republic, Austria,
Estonia, Latvia, Lithuania, Slovak Republic, Sweden, Switzerland
and the UK (Kruis 2004). In two studies (Copaci 2014; Shanahan
2006), where the setting was not explicitly stated, we have assumed
this to be the authors' aMiliation.
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Participants
In five studies reporting mean age, the average age of participants
was between 32 years in Zocco 2003 and 51 years in NCT02361957).
In five studies reporting on age range, included participants were
between 18 in Copaci 2014 and 88 years in Kruis 1997. Only one
study (Yasushi 2015), which based on its inclusion criteria may
have included paediatric patients (> 13 years). This study had an
overall mean age of 43.9 +/- 14.8 years, therefore, it is unclear
whether children were recruited. Ten out of 11 studies randomised
25 (NCT02361957) to 327 (Kruis 2004) participants. Copaci 2014
included 36 participants, some (number not stated) of which
received interventions that are outside the scope of this review.
The studies included male and female participants with ulcerative
colitis who may or may not have been receiving medication at the
time of recruitment, except for Vejdani 2017 who did not report on
age and sex, making it unclear whether the study was conducted
on adult and/or paediatric female and/or male patients. In 10
studies, participants had the following forms of ulcerative colitis:
pancolitis, leT-sided, total colitis, proctitis, proctosigmoiditis, total
colitis, subtotal colitis, distal, leT colon. However, three studies
did not provide any information on the extent of disease (Vejdani
2017; Wildt 2011; Zocco 2003). The length of time participants had
been in remission at the point of study entry was not stated in
six studies (Bjarnason 2019; Copaci 2014; NCT02361957; Shanahan
2006; Vejdani 2017; Zocco 2003), and unclear in one study (Yasushi
2015). Three studies reported at recruitment, that participants had
been in remission between one month in Kruis 1997 and Matsuoka
2018 and 12 years in Kruis 1997.
Intervention
All the included studies had two trial arms, except three studies
(Shanahan 2006; Zocco 2003; Zocco 2006), which had three trial
arms. Copaci 2014 had three trial arms, however, one arm was
excluded for assessing an intervention (prebiotic) that is not
relevant to the review. The studies investigated the following
comparisons.
• Probiotics versus placebo (Bjarnason 2019; Matsuoka 2018;
NCT02361957; Vejdani 2017; Wildt 2011; Yasushi 2015)
• Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine)
(Kruis 2004)
• Probiotics plus 5-ASA versus 5-ASA (Copaci 2014)
• Probiotics plus 5-ASA versus 5-ASA plus placebo (Kruis 1997)
• Probiotics versus probiotics versus placebo (Shanahan 2006)
• Probiotics versus probiotics plus 5-ASA versus 5-ASA (Zocco
2003; Zocco 2006)
In seven studies (Copaci 2014; Kruis 1997; Kruis 2004; Shanahan
2006; Vejdani 2017; Zocco 2003; Zocco 2006), the probiotics
contained single bacterial strains and probiotics in five studies
contained multiple strains (Bjarnason 2019; Matsuoka 2018;
NCT02361957; Wildt 2011; Yasushi 2015). These single bacterial
strains include Bifidobacterium longum (B longum) W11 (Copaci
2014), Echerichia coli (E coli) Nissle 1917 (Kruis 1997; Kruis
2004), Lactobacillus salivarius (L salivarius) UCC118 (Shanahan
2006), Bifidobacterium infantis (B infantis) 35624 (Shanahan 2006),
Lactobacillus casei (L casei) strain ATCC PTA-3945 (Vejdani 2017),
and Lactobacillus GG 18 X 109 (Zocco 2003; Zocco 2006).
In studies with multiple strain probiotics, the following
combinations were studied.
• Lactobacillus rhamnosus (L rhamnosus) NCIMB 30174,
Lactobacillus plantarum (L plantarum) NCIMB 30173,
Lactobacillus acidophilus (L acidophilus) NCIMB 30175 and
Enterococcus faecium (E faecium) NCIMB 30176 (Bjarnason 2019).
• Bifidobacterium bifidum (B bifidum) W23, Bifidobacterium lactis
(B lactis) W51, Bifidobacterium lactis (B lactis) W52, L acidophilus
W22, L casei W56, Lactobacillus paracasei (L paracasei) W20,
Lactobacillus plantarum (L plantarum) W62, L salivarius W24 and
Lactococcus lactis (L lactis) W19 (NCT02361957).
• Bifidobacterium breve (B breve) and L acidophilus (Matsuoka
2018).
• L acidophilus strain La-5 + Bifidobacterium animalis (B animalis)
subsp. lactis strain BB-12 (Wildt 2011).
• Streptococcus faecalis (S faecalis) T-110 (lactomin) + Clostridium
butyricum TO-A + Bacillus mesentericus (Yasushi 2015).
Interventions were administered daily for four weeks in Bjarnason
2019 to 52 weeks (Kruis 2004; Shanahan 2006; Wildt 2011; Yasushi
2015; Zocco 2003; Zocco 2006). Concomittant treatments were not
allowed in three studies (Kruis 2004; Wildt 2011; Zocco 2006), and
in five studies it was not explicitly stated whether concomitant
treatments were used or not. In four studies diMerent concomitant
treatments were used, such as 5-aminosalycilic preparation, low-
dose azathioprine (1 mg/kg) and prednisolone < 4 mg/day
(Bjarnason 2019), 2.4 g per day of mesalazine (NCT02361957),
aminosalicylate (Shanahan 2006), unrestricted mesalazine and
salazosulfapyridine plus topical antibiotics were not restricted
(Yasushi 2015).
Outcomes
The studies reported data on all outcomes of interest except 'need
for withdrawal of therapy'. We summarised outcome data in Table 1.
• Relapse was reported in all studies (Bjarnason 2019; Copaci
2014; Kruis 1997; Kruis 2004; Matsuoka 2018; NCT02361957;
Shanahan 2006; Vejdani 2017; Wildt 2011; Yasushi 2015; Zocco
2003; Zocco 2006). Clinical relapse was reported in six studies
(Bjarnason 2019; Kruis 1997; Kruis 2004; Matsuoka 2018; Yasushi
2015; Zocco 2006). In three studies, endoscopic and clinical
relapse were not separated out (Vejdani 2017; Wildt 2011; Zocco
2003).
• Maintenance of remission (the number of participants who
did not have a relapse) was reported in five studies (Copaci
2014; Matsuoka 2018; Wildt 2011; Yasushi 2015; Zocco 2006).
Maintenance of clinical remission was reported in three studies
(Bjarnason 2019; Yasushi 2015; Zocco 2006).
• Health related quality of life was reported in three studies
(Bjarnason 2019; Kruis 2004; NCT02361957).
• Serious adverse events were reported in seven studies
(Bjarnason 2019; Kruis 2004; Matsuoka 2018; Vejdani 2017; Wildt
2011; Yasushi 2015; Zocco 2006), although no full description
was provided. Therefore, we were unable to ascertain the
severity of the adverse events.
• Withdrawal due to adverse events was reported in five studies
(Bjarnason 2019; Kruis 1997; Kruis 2004; Wildt 2011; Zocco 2003).
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Funding and declaration of interest
The studies were government funded (Yasushi 2015), funded by
manufacturing companies (Bjarnason 2019; Kruis 1997; Matsuoka
2018), part funded by industry and a charity (Wildt 2011), and part
funded by government and industry (NCT02361957). The funding
source was not reported in six studies (Copaci 2014; Kruis 2004;
Shanahan 2006; Vejdani 2017; Zocco 2003; Zocco 2006).
Conflict of interest was not fully reported in any of the studies
except Copaci 2014, in which the authors reported that they had
none. Three studies reported that one author had no conflict
of interest (Yasushi 2015), and two authors were funded by
manufacturing companies (Bjarnason 2019; Matsuoka 2018). Two
studies reported that authors were employed by a manufacturing
company (NCT02361957; Wildt 2011). Conflicts of interest were not
reported in five studies (Kruis 1997; Kruis 2004; Shanahan 2006;
Zocco 2003; Zocco 2006).
Excluded studies
Thirty studies failed to meet the inclusion criteria and we excluded
them for the following reasons.
• Wrong study design: review (Do 2010), commentary piece
(Faubion 2000; Folwaczny 2000), not a RCT (Henker 2008; Venturi
1999).
• Wrong population: participants were not in remission at study
entry (Fujimori 2009; IRCT20120415009475N5; Li 2013; Liu
2014; Miele 2009; NCT01772615; Rembacken 1999; Sanchez-
Morales 2019; Zhang 2018a), a mixed population of active and
inactive ulcerative colitis (Ishikawa 2011), mixed population of
ulcerative colitis and Crohn's disease (Ballini 2019; Shadnoush
2013), participants had active ulcerative colitis (NCT00951548;
Palumbo 2016; Solovyeva 2014; Tursi 2010), microscopic colitis
(Rohatgi 2015).
• Wrong intervention (Bamba 2002).
• Short duration of follow-up (Ahmed 2013; Cui 2004).
• InsuMicient information on study details and no response
when authors were contacted (Ishikawa 2002; NCT00268164;
NCT00374725; NCT00803829; Pelech 1998).
Risk of bias in included studies
The studies were either at high or unclear risk of bias. The risk of
bias for the studies is summarised in Figure 2 and Figure 3. Further
details are available in the Characteristics of included studies table.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
 
 
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages




In all the included studies, allocation of participants to intervention
or placebo was described as random. The method of randomisation
was adequately described in six studies (Bjarnason 2019; Kruis
2004; NCT02361957; Vejdani 2017; Wildt 2011; Yasushi 2015), and
not described in six studies (Copaci 2014; Kruis 1997; Matsuoka
2018; Shanahan 2006; Zocco 2003; Zocco 2006). We contacted the
authors of these six studies to clarify the method of randomisation,
but did not receive further information. We rated these studies as
unclear risk of bias for sequence generation.
Allocation concealment
We rated allocation concealment as unclear for all except two
studies (Bjarnason 2019; Matsuoka 2018). We contacted the authors
to clarify allocation concealment, but did not receive a response.
The interventions in Matsuoka 2018 were delivered in identical
containers from the central pharmacy, therefore we rated this study
as low risk of bias.
Blinding
Nine of the studies were described as double-blinded (Bjarnason
2019; Kruis 1997; Kruis 2004; Matsuoka 2018; NCT02361957;
Shanahan 2006; Vejdani 2017; Wildt 2011; Yasushi 2015), and we
rated them at low risk of performance bias. However, only three
of these studies provided information (Bjarnason 2019; Kruis 2004;
NCT02361957), which suggests that blinding was maintained until
aTer outcome assessment. We rated all three studies at low risk
of detection bias, and the remaining as unclear. Copaci 2014 and
Zocco 2006 were open-label studies and we rated them at high risk
of bias. There was insuMicient information in Zocco 2003 to make a
decision, therefore it we rated it at unclear risk of performance and
detection bias.
Incomplete outcome data
Ten studies were at low risk of bias for reporting data for all
participants (Bjarnason 2019; Zocco 2003; Zocco 2006), conducting
full ITT analysis (NCT02361957; Vejdani 2017; Wildt 2011), a
combination of low attrition rates and partial ITT analysis (Kruis
1997; Matsuoka 2018), and two studies had attrition rates of > 20%
(Kruis 2004; Yasushi 2015), but balanced between both groups. Two
studies were at unclear risk of bias (Copaci 2014; Shanahan 2006).
Selective reporting
Trial registrations were available for only three studies (Matsuoka
2018; NCT02361957; Wildt 2011).
Of the seven trials which we rated at low risk of reporting bias,
two reported all outcomes which were prespecified in the trial
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registration (NCT02361957; Wildt 2011), and five had no trial
registration, but reported all expected outcomes (Bjarnason 2019;
Kruis 1997; Kruis 2004; Yasushi 2015; Zocco 2006). We rated three
studies at high risk of bias for reporting more outcomes than
specified in the protocol (Matsuoka 2018), failing to report adverse
events (Shanahan 2006), and results of biochemical tests (Vejdani
2017), Copaci 2014 and Zocco 2003 failed to provide suMicient
information for a judgement to be made (unclear).
Other potential sources of bias
We rated six studies at low risk of bias for not having other apparent
biases (Kruis 1997; Kruis 2004; NCT02361957; Vejdani 2017; Yasushi
2015; Zocco 2006). We rated three studies at high risk of bias due
to an imbalance in baseline characteristics (Wildt 2011), a posthoc
decision to discontinue the trial (Matsuoka 2018), and for being
funded by the manufacturer of the probiotic product studied with
no justification of the limits or level of involvement (Bjarnason
2019)
E;ects of interventions
See: Summary of findings for the main comparison Probiotics
compared to placebo for maintenance of remission in ulcerative
colitis; Summary of findings 2 Probiotics compared to 5-
aminosalicylic acid (5-ASA) (mesalazine) for maintenance of
remission in ulcerative colitis; Summary of findings 3 Probiotic
+ 5-aminosalicylic acid (5-ASA) (mesalazine) compared to 5-ASA
(mesalazine) for maintenance of remission in ulcerative colitis
Probiotics versus placebo
Seven studies compared probiotics with placebo (Bjarnason 2019;
Matsuoka 2018; NCT02361957; Shanahan 2006; Vejdani 2017; Wildt




We found very low-certainty evidence that, on average, there was
no clear diMerence in the incidence of clinical relapse between
probiotics and placebo (risk ratio (RR) 0.87, 95% confidence interval
(CI) 0.63 to 1.18; 4 studies, 361 participants; very low-certainty
evidence; Analysis 1.1, Figure 4). We downgraded the evidence
three times for high risk of reporting and other bias due to
imbalance in baseline characteristics, and imprecision due to small
sample size.
 
Figure 4.   Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.1 Clinical relapse.
 
Two other studies also reported on relapse (Vejdani 2017; Wildt
2011). In these studies, relapse data appear to have included a mix
of endoscopic and clinical relapse. Vejdani 2017 defines relapse as:
an increase in bowel frequency with blood for at least one week and
a colonoscopy and biopsies to confirm relapse. Wildt 2011 defines
relapse as: simple clinical colitis activity index (SCCAI) score > 4 and/
or endoscopic changes grade 2 to 3. Due to concerns about clinical
heterogeneity, we did not analyse the data. Number of relapses in
the probiotics compared to the placebo group were 4/14 (28.6%)
versus 7/15 (46.7%) in Vejdani 2017 and 15/20 (75%) versus 11/12
(91.7%) in Wildt 2011.
Maintenance of clinical remission
The number of participants who remained in clinical remission,
i.e. did not have a relapse, was reported in three studies. It is
uncertain whether probiotics lead to a diMerence in maintenance
of remission when compared with placebo (RR 1.16, 95% CI 0.98
to 1.37; 2 studies, 141 participants; very low-certainty of evidence;
Analysis 1.2). We downgraded the evidence three times for high risk
of bias and imprecision due to wide CIs, which includes appreciable
harm. One additional study with 205 participants (Matsuoka 2018),
reported insuMicient data for inclusion in the meta-analysis; we did
not analyse the results further.
Wildt 2011 reported on the number of participants who remained
in remission, however, the definition of the relapse suggests that
the data potentially includes participants in endoscopic and clinical
remission. The number of people on probiotics who remained in




In four studies with 351 participants which reported on serious
adverse events, no events were recorded (Analysis 1.3, Figure 5).
 
Probiotics for maintenance of remission in ulcerative colitis (Review)









Cochrane Database of Systematic Reviews
Figure 5.   Forest plot of comparison: 1 Probiotics versus placebo, outcome: 1.3 Serious adverse events.
 
Withdrawal due to adverse events
Two studies with 113 participants indicated that there were no
withdrawals as a result of adverse events (Bjarnason 2019; Wildt
2011).
Need for additional therapy
This outcome was not reported.
Health-related quality of life
Health-related quality of life was reported in two studies and
measured using the inflammatory bowel disease questionnaire
(IBD-Q) scale in one of them (NCT02361957), and the UK IBD-Q in
the other one (Bjarnason 2019). The IBD-Q scale ranges from 1 to
7, with a higher score representing better quality of life. We found
low-certainty evidence that, on average, probiotics made no clear
diMerence in health-related quality of life compared with placebo
(mean diMerence (MD) -0.70, 95% CI -1.63 to 0.23; 1 study, 25
participants; low-certainty evidence; Analysis 1.5). We downgraded
the evidence twice for imprecision due to inadequate sample size
from a single study with wide CIs. The UK IBD-Q is similar, however,
the authors that used it reported separately on the five overall
parameters of the questionnaire (emotional symptoms, bowel
function-1, social function, bowel function-2, systemic function). As
there was no overall score reported, we could not include a quality
of life value in our meta-analysis.
Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine)
Three trials compared probiotics with 5-ASA (Kruis 2004; Zocco
2003; Zocco 2006). See Summary of findings 2.
Primary outcome
Clinical relapse
We found low-certainty evidence that, on average, there was no
clear diMerence in the incidence of relapse between probiotics and
5-ASA (RR 1.01, 95% CI 0.84 to 1.22; 2 studies, 452 participants;
low-certainty evidence; Analysis 2.1). We downgraded the evidence
twice for high risk of bias and imprecision due to the inadequate
sample size.
In Zocco 2003, relapse was defined "by clinical and endoscopic
features". Due to the heterogeneity, we decided not to analyse
the data. The number of relapses in the probiotics versus placebo
group were 2/12 (16.7%) versus 2/10 (20%), respectively.
Maintenance of clinical remission
We found low-certainty evidence that, on average, probiotics
showed no clear diMerence in maintenance of clinical remission
when compared with 5-ASA (RR 1.06, 95% CI 0.90 to 1.25;
1 study, 125 participants; low-certainty evidence; Analysis 2.2).
We downgraded the evidence twice for high risk of bias and
imprecision due to a small number of events.
Secondary outcomes
Serious adverse events
It is uncertain whether probiotics lead to a diMerence in serious
adverse events when compared with 5-ASA (RR 1.19, 95% CI 0.41 to
3.46; 1 study, 327 participants; very low-certainty evidence; Analysis
2.3). We downgraded the evidence three times for high risk of
bias and imprecision due to the small number of events and wide
confidence interval, which includes appreciable harm.
Withdrawal due to adverse events
It is uncertain whether probiotics lead to a diMerence in serious
adverse events when compared with 5-ASA (RR 1.02, 95% CI 0.46 to
2.25; 1 study, 222 participants; very low-certainty evidence; Analysis
2.4). We downgraded the evidence three times for high risk of bias
and imprecision due to the small number of events in a single study
and wide confidence interval, which includes appreciable harm.
Need for additional therapy
This outcome was not reported.
Health-related quality of life
One study reported quality of life scores at 12 months based
on the IBDQ scale, ranging from 0 to 32, with a higher score
representing a better quality of life (Kruis 2004). We found low-
certainty evidence that there was no clear diMerence in health-
related quality of life between probiotics and 5-ASA (MD -0.80, 95%
CI -2.01 to 0.41; 1 study, 222 participants; low-certainty evidence
Analysis 2.5). We downgraded the evidence twice for high risk of
bias and imprecision due to small sample size.
Probiotic + 5-ASA (mesalazine) versus 5-ASA (mesalazine)
Four trials compared a probiotic plus 5-ASA with 5-ASA alone
(Copaci 2014; Kruis 1997; Zocco 2003; Zocco 2006). See Summary of
findings 3.
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Primary outcome
Clinical relapse
It is uncertain whether probiotics combined with 5-ASA leads to a
diMerence in the incidence of relapse when compared with 5-ASA
alone (RR 1.11, 95% CI 0.66 to 1.87; 2 studies, 242 participants;
very low-certainty evidence; Analysis 3.1). We downgraded the
evidence three times for high risk of bias and imprecision due to
the small number of events and confidence interval, which includes
appreciable benefit or harm.
In Zocco 2003, relapse was defined "by clinical and endoscopic
features". Due to the heterogeneity, we were unable to analyse the
data. The number of relapses which occurred in the probiotics and
5-ASA group compared to 5-ASA alone was 4/14 (28.6%) versus 2/10
(20%).
Maintenance of clinical remission
The number of participants who remained in remission, i.e. did
not have a relapse, was reported in two studies. We found low-
certainty evidence that, on average, probiotics combined with and
5-ASA showed no clear diMerence in maintenance of remission
compared with 5-ASA alone (RR 1.05, 95% CI 0.89 to 1.24; 1 study,
122 participants; Analysis 3.2). We downgraded the evidence twice




This outcome was not reported.
Withdrawal due to adverse events
It is uncertain whether probiotics combined with 5-ASA leads to
a diMerence in withdrawal due to adverse events compared with
5-ASA alone because the certainty of the evidence is very low.
One study reported there were no withdrawals due to adverse
events and one study reported two withdrawals in the probiotics
combined with 5-ASA group (RR 5.29, 95% CI 0.26 to 107.63; 2
studies, 127 participants; very low-certainty evidence; Analysis
3.3). We downgraded the evidence three times for unclear risk
of selection bias, small number of events and wide confidence
interval, which includes appreciable harm.
Need for additional therapy
This outcome was not reported.
Health-related quality of life
This outcome was not reported.
Sensitivity analysis
We carried out sensitivity analyses using an available case analysis
versus intention-to-treat (ITT) analysis as well as fixed-eMect versus
random-eMects models. We did not find any diMerences between
either set of analyses. See full data in Table 2.
D I S C U S S I O N
Summary of main results
This review included 11 parallel group randomised controlled trials
(RCTs) assessing the eMectiveness of probiotics for the maintenance
of remission in ulcerative colitis. All the studies, except two (Copaci
2014; Shanahan 2006), provided suMicient data for inclusion in
a meta-analysis. The comparisons assessed by the studies were
probiotics versus placebo, probiotics versus 5-aminosalicylic acid
(5-ASA) and probiotic plus 5-ASA versus 5-ASA . We analysed and
summarised data from nine studies (1031 participants): Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3. It is uncertain if there is any diMerence
in occurrence of clinical relapse when probiotics are compared
with placebo (very low-certainty evidence). When probiotics were
compared with 5-ASA, there was no clear diMerence in relapse
(low-certainty evidence). It is uncertain whether probiotics lead
to a diMerence in maintenance of remission when compared with
placebo because the certainty of the evidence is very low. There is
no clear diMerence in maintenance of remission when probiotics are
compared with 5-ASA, neither is there a diMerence when probiotics
combined with 5-ASA is compared with 5-ASA alone (low-certainty
evidence). It is uncertain whether probiotics combined with 5-ASA
leads to a diMerence in the incidence of relapse when compared
with 5-ASA alone because the certainty of the evidence is very low.
The studies comparing probiotics with placebo reported that no
serious adverse events occurred. One study comparing probiotics
and 5-ASA reported on similar numbers of serious adverse events
in both groups. Further details were not provided on these serious
adverse events.
No diMerence in eMicacy was found between probiotics and
placebo, which could reflect the clinical truth of no eMicacy
regarding these agents. However, no diMerence was found between
probiotics and 5-ASA either. This is key, as 5-ASA are generally used
as standard first-line interventional therapy, with their eMicacy well
demonstrated in previous systematic reviews (Wang 2016). As such,
given the lack of eMicacy of probiotics compared with placebo, it
would be expected that they would be inferior to 5-ASA as standard
therapy, which has not been demonstrated. We do not have enough
evidence in this current synthesis to demonstrate the eMicacy of
probiotics, but feel these inconsistencies raise genuine questions
for clinicians, researchers and users in the field.
Overall completeness and applicability of evidence
The capricious body of evidence synthesised in this review is highly
heterogenous in terms of population and intervention, and as such,
significantly limits its applicability to guide decision making. In
considering application of the evidence, clinicians and patients
require not just statistically significant results; the results need to
reflect specific clinical contexts and problems for which they can
apply these solutions. It is particularly striking that on updating this
review aTer almost 10 years, the body of evidence has grown but is
still far from complete and unable to be applied to practice.
The studies involved a wide range of people who had been in
remission for various lengths (> 1 month to 12 years), but as
recruiting studies ubiquitously made such judgements on clinical
grounds, with the addition of activity scores, consideration of
concepts, such as 'deep remission', which are key in practice,
is completely absent from the discourse in these trials. The
weaknesses of the primary studies have not allowed exploration
of such wide ranging participant characteristics through subgroup
analysis, which would be key for implementation of any findings
from such a review.
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There was minimal consideration of children in included studies,
with all except Yasushi 2015 recruiting only adults. Based on its
inclusion criteria, Yasushi 2015 attempted to recruit both adult and
paediatric patients, but it is not clear if they actually achieved
this, treating them as one population. As such, the applicability
of this evidence to paediatric patients is a significant concern.
Furthermore, almost half of the studies excluded participants who
were receiving immunosuppressants at the point of recruitment,
suggesting a preference for people with mild disease severity. This
should be considered in applying the evidence in practice.
Study participants received probiotics which had either single
or multiple strains for a maximum period of 12 to 52 weeks.
Whilst it is common for reviews within Cochrane and the wider
field to synthesis evidence that considers probiotics as a single
interventional group, subgroup analysis is key for what are
eMectively a disparate family of interventional agents, and once
again the limitations of the evidence in this review has not allowed
this to be completed.
Relapse and maintenance of remission were reported in most
of the studies. However, most of the secondary outcomes were
not suMiciently reported. Serious adverse events were reported,
however, this outcome was not described at all in any of the
studies. Health-related quality of life and withdrawal due to adverse
events were rarely reported. Need for withdrawal of therapy was
not reported in any of the included studies. The eMect of probiotics
on these secondary outcomes remains unclear.
Certainty of the evidence
The certainty of evidence was either low or very low due to
risk of bias and imprecision. Eight studies were at high risk of
bias and three studies were at unclear risk of bias. Most of
the studies failed to provide suMicient information on allocation
concealment. Though the studies which used double-blinding had
clearly included placebo or provided control which was identical
to the study intervention to prevent performance bias, it was
not explicitly stated whether outcome assessment was blinded or
not. Indicating that a study was double-blinded without explicitly
stating who (participants, caregiver, outcome assessor, etc.) the
blinding was applied to is usually not helpful in 'Risk of bias'
assessment. Five studies were published as abstracts and were at
unclear risk of bias for most domains.
The studies had sample sizes of between 25 and 327 participants.
We downgraded for imprecision as the trials either had small
numbers of events or small sample sizes which were insuMicient
to meet the optimal information size, thus resulting in wide
confidence intervals. Whilst power calculations were used, they
were oTen based on estimates of eMect, rather than previous
trial data, and therefore this raises the question as to whether
these studies were adequately powered. The definition of relapse
reported in some of the studies suggests that people with
endoscopic and clinical relapse or remission may have been
lumped together. We carried out a narrative synthesis of such
studies since they were dissimilar to the studies which clearly
reported on clinical relapse only. This reduced the amount of data
that were pooled for the outcome of clinical relapse/remission and
increased imprecision.
Most of the analyses involved single studies. Where there was
suMicient data for pooling, there was no heterogeneity (I2 = 0%).
Therefore, there was no reason to downgrade for inconsistency.
There was no indirectness, as the included studies all addressed
the objectives of the review and fit within the scope. The number
of studies included in the meta-analysis was insuMicient to assess
for publication bias.
The inconsistency within results has already been discussed, with
no diMerence between probiotics and placebo nor probiotics and 5-
ASA (a standard treatment with proven superiority over placebo).
This point is highlighted in the context of the quality issues raised,
given that all but one study comparing probiotics and placebo was
at high risk of bias. It is therefore likely that this is the source of the
inconsistency and is a key message for future researchers.
Potential biases in the review process
We are aware of the biases that could arise from missing data
and made eMorts to contact authors for additional information and
clarifications. However, most of the authors we contacted failed to
reply. To minimise bias, we included such studies in our narrative
synthesis and carried out sensitivity analyses, where possible, to
provide a conservative estimate of eMect. We aim to include any
data which become available from authors in future updates.
Other limitations in the review process are to do with risk of bias of
individual studies. Three of the included studies are only available
as abstracts. This meant that the studies had to be marked at
unclear risk of bias for most of the domains. Given that we did not
carry out sensitivity analyses to examine their impact on the results
due to the insuMicient number of studies included in each meta-
analysis, the inclusion of these abstracts may further influence the
validity of the data.
Finally, we are aware of the possible impact of industry funding on
the validity of trial results. Funding from probiotic manufacturing
companies or inclusion of company staM in the author team was
noted in some of the studies and we considered the impact of this
information on the 'Risk of bias' assessment of the studies and
GRADE assessment of the evidence. Given that none of the studies
showed a clear diMerence in favour of probiotics, we assumed that
industry funding is unlikely to have compromised the results of this
review.
Agreements and disagreements with other studies or
reviews
There is currently no other known evidence-based guidance
or systematic review around the use of probiotics for the
maintenance of remission in ulcerative colitis, apart from the
previous version of this review (Naidoo 2011). The European
Crohn's and Colitis Organisation (ECCO) and European Society of
Paediatric Gastroenterology, Hepatology and Nutrition (ESPHGAN)
guideline briefly described the evidence on the eMicacy of
probiotics and made no recommendation regarding its use for
the maintenance of remission (Turner 2018). The current National
Institute for Health and Care Excellence (NICE) guideline does
not cover probiotics either (NICE 2013). This review has found
insuMicient evidence on the eMect of probiotics for maintenance
of remission in ulcerative colitis, and therefore retains the same
conclusion from Naidoo 2011.
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A U T H O R S '   C O N C L U S I O N S
Implications for practice
The eMectiveness of probiotics for the maintenance of remission
in ulcerative colitis remains unclear. This is due to low- to
very low-certainty evidence from poorly conducted studies,
which contribute limited amounts of data from a small number
of participants. It is uncertain whether probiotics lead to a
diMerence in clinical relapse and the maintenance of remission
when compared with placebo (very low-certainty evidence).
Probiotics were compared with 5-aminosalicylic acid (5-ASA)
(conventional therapy) and there was no clear diMerence in relapse
or maintenance of remission (low-certainty evidence). There were
no serious adverse events in all but one study, which reported
similar numbers across the probiotics and 5-ASA groups, however,
no further details were reported. Health-related quality of life and
withdrawal due to adverse events were rarely reported.
Implications for research
This review highlights the need for further well-designed
randomised controlled trials (RCTs) to investigate the eMicacy and
safety of probiotics for the maintenance of remission in ulcerative
colitis. However, we believe it is key to define contextually what
the attributes of such trials should be. The majority of the
trials compared probiotics with placebo. Future trials comparing
probiotics with 5-ASA would reflect conventional care given to
people with ulcerative colitis. Additionally, the length of follow-
up of most studies in this review is much less than in studies
assessed by other published reviews on maintenance therapy.
Maintenance studies investigating treatment eMects for less than
12 months are simply too short to inform clinical practice, where
the attrition rates from remission are such that a minimum of one
year should be considered for study. We would also strongly suggest
that study investigators work to ensure the homogenous nature of
their baseline populations from a disease activity standpoint, as
we believe it is diMicult to consider patients in remission for one
month on recruitment the same as those who are 12 years into
their remission. The question of sample size is also a major concern,
with a minimal use of power calculations using expected eMect
sizes which were estimated in wide ranging ways and have led to
11 studies with a little over 1000 participants. Given other studies
exhibited in other reviews in the field, particularly the high placebo
response rate seen (Jairath 2017), we believe it is likely that such
calculations were too optimistic in projected eMect sizes, and as
such, may have been underpowered to appropriately investigate
the agents under study. Considering the ongoing trials, none of
these appears to be of the statistical power or length of follow up
to address these issues.
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Characteristics of included studies [ordered by study ID]
 
Methods RCT, double-blind, single centre
Setting: King's College Hospital Gastroenterology Clinic, London
Study duration: November 2010 to October 2014
Participants 81 patients with UC, 61 patients with CD (total IBD = 142)
Inclusion criteria: patients attending routine clinical review with established UC and CD, age 18 to 70
years, diagnosed at least 6 months prior to the trial; patients were required to have stable inactive clin-
ical disease, as defined by < 5 points on Harvey Bradshaw (which corresponded to a score of ≤ 4 on the
Truelove-Witts criteria for UC, without a change in medication for 4 months. Patients on no treatment,
maintenance treatment with a 5-aminosalycilic preparation or low-dose azathioprine (1 mg/kg) were
eligible for inclusion in the trial.
Exclusion criteria: patients on steroids (prednisolone > 4 mg/day) and biologics were excluded from
the study; patients having undergone intestinal resection, patients with serious comorbidity including
neurological, rheumatological, respiratory, nephrological, cardiovascular, psychiatric disease, patients
with alcohol or drug addiction or dependency problems (within the last 5 years) and pregnant or lac-
tating women; patients with previous intolerance or adverse reactions to probiotics or the use of these
products within the preceeding 3 months were excluded.
Age (mean +/- SD): probiotic UC 47.3 +/- 14.4, placebo UC: 43.4 +/- 12.1; probiotic CD: 41.2 +/- 13.0,
placebo CD: 39.0 +/- 13.0
Sex: not specified
Site of disease: probiotics UC: proctosigmoid 16, leT-sided 9, pancolonic 12; placebo UC: proctosig-
moid 21, leT-sided 10, pancolonic 9
probiotics CD: small bowel 14, colon 11, small and large bowel 9; placebo CD: small bowel 14, colon 7,
small and large bowel 7
Use of medication: probiotics UC: 5-ASA 31, azathioprine 2, prednisolone 1, none 7
placebo UC: 5-ASA 33, azathioprine 2, prednisolone 0, none 6
probiotics CD: 5-ASA 15, azathioprine 4, prednisolone 1, none 13
placebo CD: 5-ASA 12, azathioprine 2, prednisolone 0, none 15
Length of time remission at study entry: not specified
Number randomised: total probiotic: 73, total placebo: 70; probiotic UC: 40, placebo UC: 41; probiotic
CD: 33, placebo CD: 29
Number assessed: all randomised completed the study
Postrandomisation exclusion: 0
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No significant side effects were reported and the probiotic was well-tolerated by everyone
Interventions Follow-up: 4 weeks
IV: Symprove (Symprove Ltd. Farnham, Surrey UK), a dietary food supplement which contains 4 strains
of bacteria (Lactobacillus rhamnosus NCIMB
30174, Lactobacillus plantarum NCIMB 30173, Lactobacillus
acidophilus NCIMB 30175 and Enterococcus faecium
NCIMB 30176), in a water-based suspension of barley extract with each 50 mL/dose containing about 10
billion live bacteria.
Control: patients received placebo, which was an identical liquid in appearance and taste, containing
water and flavouring and was provided in identical packaging supplied by the manufacturers identified
by a trial batch and code number only. Patients were asked to keep the study medication refrigerated
between 2 °C and 7 °C and to self-administer 1 mL/kg
each morning on a fasting stomach. Foods and fluids were allowed 20 min later. Missed does could be
taken later during the day provided that no food had been consumed during
the preceding 3 hours.
Outcomes Primary efficacy outcome: difference in overall change in the IBD QoL questionnaire results at week 4
Secondary measures: the differences in clinical disease activity scores between active and placebo
treatment and changes in laboratory measures including FCAL (Ek-CAL, Buhlmann, Switzerland)
Notes Funding and conflict of interest: supported by an unreserved research grant from Symprove Limited,
the manufacturers of the probiotic Symprove to King's College Hospital. They also provided the probi-
otic used in the trial and a matching placebo free of charge. Prof Bjarnason has received financial sup-
port from Symprove Ltd for travel expenses to scientific meetings.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Study participants were randomised using a two-stage computerised




Low risk It is explained that preparations were identical liquids in appearance and
taste, provided in identical packaging supplied by the manufacturers, identi-
fied by a trial batch and code number only, however no other information on





Low risk Quote: "Blinding of allocation to treatment was maintained until the complet-
ed study database was locked and passed over to an independent study statis-
tician".
Double-blinding. Preparations were identical liquids in appearance and taste,
provided in identical packaging supplied by the manufacturers, identified by a
trial batch and code number only
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Blinding of allocation to treatment was maintained until the complet-





Low risk All reported
Selective reporting (re-
porting bias)
Low risk All reported
Bjarnason 2019  (Continued)
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Other bias High risk The study was funded by the manufacturers of the probiotics product studied





Methods Open-label, parallel group, randomised clinical trial (abstract only)
Setting: not stated, however authors' affiliation - Fundini clinical institute, Bucharest, Romania
Study period: not stated
Participants Inclusion criteria: people with UC in remission for over 3 months
Exclusion criteria: not stated
Age (range): 18 to 65 years
Sex: not stated
Site of disease: ? (total colitis), ? (leT-sided colitis)
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised (n = 36): ? (probiotic + mesalamine)/? (mesalamine + prebiotic)*/? (mesalamine)
Number assessed: ? (probiotic + mesalamine)/? (mesalamine + prebiotic)*/? (mesalamine)
Postrandomisation exclusion: not stated
Interventions • Mesalazine plus probiotic (Bifidobacterium longum W11)
• Mesalazine plus prebiotic (Plantago Ovata)*
• Mesalazine
Outcomes Duration of follow-up: 24 weeks
• Relapse
• Continued remission. Remission - not defined
• Safety (Gastrointestinal Symptom Rating Scale (GSRS): 1 to 7 - higher score = more troublesome symp-
tom)
Notes Funding source: not stated
Declaration of interest: reported, none declared
*Disregarded prebiotic data for not being within the scope of the review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Open-label, parallel group, randomized clinical trial".
Comment: not adequately described
Copaci 2014 
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Allocation concealment
(selection bias)





High risk Quote: "Open-label, parallel group, randomized clinical trial"
Comment: there was no blinding of participants and personnel
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Unclear risk Not adequately reported
Selective reporting (re-
porting bias)
Unclear risk Symptoms were monitored using a gastrointestinal symptom rating scale,
however, the results were not fully reported




Methods Double-blind, multicentre RCT
Setting: outpatient hospitals and private practices in Germany, the Czech Republic and Austria
Study period: not stated
Participants Inclusion: age > 17 years; presence of chronic UC currently in remission (defined by CAI score)
Exclusion: active UC, infectious colitis, existing or intended pregnancy, any other medication for UC
besides the study drugs, antibiotics or suphonamides, substantial cardiac, hepatic or renal disease,
major operations on the bowels, and known intolerance to salicylates
Age* (range): 19 to 88 years
Sex* (M/F): 55/48
Site of disease*: 28 (proctitis); 40 (proctosigmoiditis); 19 (leT-sided colitis); 18 (total/subtotal colitis)
Use of medication*: 82 (salicylates); 25 (corticosteroids)
Length of time remission at study entry: 14 (1 to 147 (probiotic)/12 (1 to 60) months (mesalazine)
Number randomised (n = 120): 60? (probiotics)/60? (mesalazine)
Number assessed: 50 (probiotics)/53 (mesalazine)
Postrandomisation exclusion: 2 - not started taking study medication, 15 - had CAI of > 4 (8 versus 7)
Interventions • Probiotics + mesalazine placebo: oral preparation containing E coli strain Nissle 1917. 200 mg/day
(day 1 to 4, only 100 mg/day) of a preparation of viable E coli strain Nissle 1917 (Mutaflor, Ardeypharm
GmbH, Herdecke, Germany) taken as a single dose during breakfast. Mutaflor 100 mg contains 25 X
109 viable E coli bacteria
• Mesalazine + placebo: 500 mg mesalazine three times a day (Salofalk, Dr Falk Pharma GmbH, Freiburg,
Germany) plus placebo indistinguishable from the E coli preparation
Outcomes Duration of follow-up: 12 weeks (in one centre the total study period was 24 weeks)
Kruis 1997 
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• Relapse defined as CAI > 4
• Relapse-free time
• Adverse events
• Withdrawal due to adverse events
Notes Funding source: supported by Ardeypharm GmbH, Herdecke, Germany
Declaration of interest: not reported.
*Baseline characteristics reported do not account for participants who were excluded postrandomisa-
tion
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Participants were reportedly randomised, however, the method of randomisa-
tion was not adequately described
Allocation concealment
(selection bias)





Low risk Described as double-blind double-dummy. Both intervention arms included
placebos.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Described as double-blind double-dummy, however, there was no specific in-




Low risk ITT analysis (modified ITT) was partially applied as it failed to account for
participants who were excluded postrandomisation. However, number and
reasons for postrandomisation exclusion appear to have been equal across
groups (16% versus 11%)
Selective reporting (re-
porting bias)
Low risk Trial registration was not available, however, all expected outcomes were re-
ported




Methods Double-blind, multicentre RCT
Setting: 60 hospitals and private settings in 10 European countries (Austria, Czech Republic, Estonia,
Germany, Latvia, Lithuania, Slovak Republic, Sweden, Switzerland, UK)
Study period: not stated
Participants Inclusion: age 18 to 70; UC in remission (CAI ≤ 4, endoscopic index ≤ 4 and no sign of acute inflamma-
tion on histological examination); at least two acute attacks of UC prior to study; time since last re-
lapse: < 12 months
Exclusion: active UC; proctitis with up to 10 cm proximal spread; Crohn's disease, infectious colitis; se-
vere accompanying illnesses or major colonic surgery; use of antibiotics, sulphonamides, steroids or
Kruis 2004 
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other therapies for UC at entry into trial; administration of study intervention drug within the previous
six months before trial entry; known intolerance to salicylates
Age: 19 to 82 years
Sex (M/F): 179/148
Site of disease: 61 (sub/total); 62 (leT-sided); 190 (distal)
Use of medication: 235 (oral salicylates - partly combined with steroids)
Length of time remission at study entry: < 4 (probiotic)/< 3 months (mesalazine)
Number randomised (n = 327): 162 (probiotic)/165 (mesalazine)
Number assessed: 162 (probiotic)/165 (mesalazine)
Postrandomisation exclusion*: 2 - deterioration of disease excluding relapse; 6 - newly emerged ex-
clusion criterion during study; 22 - patient's request; 9 - adverse events; 12 - insufficient patient compli-
ance; 9 - insufficient patient co-operation; 7 - dropped out; 3 - other; premature discontinuation - 39
Interventions • Probiotic + placebo: oral preparation containing E coli strain Nissle 1917. Capsules contained 2.5 to 25
X 109 viable bacteria (Mutaflor 100 mg; Ardeypharm GmbH, Herdecke, Germany). Participants received
one capsule of Mutaflor 100 mg once daily and one tablet of placebo 3 x daily for 4 days and 2 capsules
of Mutaflor 100 mg once daily and one tablet of placebo 3 x daily from day 5 to the end of the study
• Mesalazine + placebo: 5-aminosalicylic acid (Salofalk, Dr Falk Pharma GmbH, Freiburg, Germany). Par-
ticipants received one capsule of placebo once daily and one tablet of Salofalk 500 mg 3 x daily for 4
days and two capsules of placebo once daily and one tablet of Salofalk 500 mg 3 x daily from day 5
to the end of the study
No concomitant medication for UC was allowed throughout the study
Outcomes Duration of follow-up: 12 months
• Relapse defined as presence of all of the following: CAI > 6 (or an increase in CAI of at least 3 points
with CAI = 4 being exceeded at the same time); endoscopic index > 4; histological signs of acute in-
flammation
• Quality of life at 12 months
• Serious adverse events
• Adverse events requiring withdrawal of therapy
Notes Funding source: not stated
Declaration of interest: not reported
*some participants may have had multiple reasons for being excluded
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomisation was carried out in a double blind manner in blocks of
four patients using 1:1 allocation to the two treatment groups. Only complete
blocks of random numbers were used for each centre. If patients were eligible
for study entry, they were assigned to random numbers ( = patient numbers)
in ascending order within each centre according to the chronological order of




Unclear risk Confirmed via correspondence (quote): "Since Mutaflor and Mesalazine have
a different dosage form (capsule vs. tablet), the double-dummy method was
used to ensure double-blindness, i.e. a patient allocated to the test group was
Kruis 2004  (Continued)
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given Mutaflor verum and Mesalazine placebo, whereas a patient allocated to
the control group was given Mesalazine verum and Mutaflor placebo)"






Low risk Described as double-blind and double-dummy
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Before unblinding the study, a steering committee assessed protocol
violations in 105/327 (32.1%) patients."





Low risk High attrition, but balanced between the two groups.
Selective reporting (re-
porting bias)
Low risk Trial registration not available, however, all measured outcomes were report-
ed
Other bias Low risk Quote: "The two patient groups were matched with regard to demographic,
clinical, and pretreatment characteristics"




Methods Double-blind, parallel group, Multicentre RCT
Setting: Keio University School of Medicine; Tokyo Yamate Medical Center, Center for Infammatory
Bowel Disease; Toho University Medical Center, Sakura Hospital; Kitasato University Hospital; Yoko-
hama City University Medical Center, Infammatory Bowel Disease Center; Kannai-Suzuki Clinic; and
Matsushima Clinic, Japan
Study period: April 2012 to September 2013
Participants Inclusion: diagnosed with UC, in remission, age 20 to 70, worsening symptoms within 2 years, defined
as one or more of the following criteria:
• persistent bloody stool > 1 week
• initiation of 5-ASA treatment, dose escalation, change in medication type for worsening symptoms
• initiation or dose escalation of cytapheresis or glucocorticoids
• initiation or dose escalation of immuno modulators, immunosuppressants, anti-tumour necrosis fac-
tor
Exclusion:
• Diagnosed with proctitis-type UC
• Visible bloody stools detected < 4 weeks before enrolment
• Dose modification of 5-ASA, or change in medication for worsened UC < 4 weeks before enrolment
• Local administration of 5-ASA
• Administration of cytapheresis < 4 weeks before enrolment
• Administration of immunomodulators (azathioprine, mercaptopurine) immunosuppressants
(tacrolimus, cyclosporin) or anti-tumour necrosis factor (infliximab) < 12 weeks before enrolment
Matsuoka 2018 
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• Unable to stop regular consumption of probiotic products other than the study beverage, or food
products using lactic acid bacteria during the study period
• Regular consumption of B breve strain Yakult used in the study < 10 days before enrolment
Age: 20 to 70 years
Sex (M/F): 100/92
Site of disease: 100 (pancolitis); 92 (leT-sided colitis)
Use of medication: 190 (5-ASA)
Length of time remission at study entry (mean/range): 362.7 (54 to 750) - probiotic/378.6 (41 to 846)
days - placebo
Number randomised (n = 195)*: 98 (probiotics)/97 (placebo)
Number assessed: 97 (probiotics)/95 (placebo)
Postrandomisation exclusion**: 67 - discontinuation of protocol specified treatment, 10 - prohibited
concomitant treatment, 2 - adverse events, 13 - discontinuation of study beverage, 1 - other
Interventions • Probiotic: one pack of B breve strain Yakult fermented milk (Mil–Mil) (10 billion bacteria) and Lacto-
bacillus acidophilus (1 billion bacteria) per day
• Placebo: one pack of energy beverage per day
All participants received their allocated treatment for 48 Weeks
Outcomes Duration of follow-up: 48 weeks
• Incidence of relapse. Relapse defined as: persistence of a rectal bleeding score of greater or equal than
2 on Sutherland DAI score for 3 consecutive days and/or initiation of remission induction therapy for
worsening of UC (as judged by investigator )
• Maintence of remission. Remission defined as: Sutherland disease activity index (DAI) scale with rectal
bleeding score of 0 and an endoscopic score of 0 or 1
• Serious adverse events
Notes Funding source: "This work was supported by Yakult Honsha Co., Ltd."
Declaration of interest: reported; Takanori Kanai received a financial donation from Yakult. Yasuo
Suzuki, Toshifumi Hibi, Yukari Uemura, Kaoru Yokoyama, Naoki Yoshimura, Reiko Kunisaki, and Kat-
suyoshi Matsuoka have no conflicts of interest to declare
*Statistical power calculated 300 in each intervention arm needed. However, study split into Period 1
and Period 2. Only period 1 conducted - this used 97 in intervention and 95 in control
**Some participants discontinued for multiple reasons
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patient data were sent to the registration center via facsimile, where
randomization was implemented by the central registration method. A statis-
tician determined the algorithm of allocation. Patients were randomly allocat-
ed to the BFM group or placebo group at a ratio of 1:1 by dynamic allocation
with the following randomization factors: age (≥ 40 years/12 weeks), study site
(each study site), and compliance with 5-ASA"
Comment: algorithm was determined by a statistician based on age, study site
and compliance with 5-ASA as opposed to a computer
Matsuoka 2018  (Continued)
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Allocation concealment
(selection bias)
Low risk Quote: "The study beverage and placebo beverage were packaged to be indis-
tinguishable in appearance from each other and were delivered from the dis-
tribution center based on the allocation results at the time of enrolment. The
distribution center, which was not informed of the groups to which patients
were allocated, delivered the study beverage according to the provided num-
bers; this maintained blindness of the study."





Low risk Quote: "BFM and placebo consisted of 100 mL of an opaque white liquid that
were identical"
Comment: similar opaque liquid used
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The trial was described as double-blinded, however, it is not clear if this in-
cludes blind outcome assessment. Though there was an independent da-





Low risk Data analysed based on the "full study set". This full study set does not include
all participants who were randomised, however, the difference (1 versus 1)
across groups and reasons appear to be balanced
Selective reporting (re-
porting bias)
High risk Trial registration available (UMIN000007593), however, there were more out-
comes reported in the trial than prespecified
Other bias High risk Quote: "The interim analysis results showed that the Bayesian predictive pow-
er was 3.7%, which was markedly lower than the reference range for study
continuation (20–25%). Based on this, the Independent Data Monitoring Com-
mittee recommended discontinuation of the study, so the study was discontin-
ued"
Comment: a posthoc decision was made to discontinue the study. This was not




Methods Double-blind, single centre RCT
Setting: Hospital Gelderse Valei (Ede, The Netherlands)
Study period: not stated
Participants Inclusion: age 18 to 65; leT-sided UC or pancolitis in clinical remission (serum concentrations of C-re-
active protein of < 10 mg/L, which was checked with a point-of-care CRP test, and calprotectin of < 100
μg/g during their last medical check-up)
Exclusion: history of GI surgery, diabetes mellitus, cancer; use of antibiotics during the last 3 months;
current use of corticosteroids; alcohol consumption ≥ 21 servings a week for men and ≥ 14 for women;
hypersensitivity to milk protein, gluten, or soy protein; currently pregnant or breastfeeding
Age (mean ± SD): 51.5 ± 12.4 years
Sex (M/F): 13/12
Site of disease: ? (leT-sided), ? (pancolitis)
Use of medication: not stated
NCT02361957 
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Length of time remission at study entry: not stated
Number randomised (n = 25): 13 (probiotic)/12 (placebo)
Number analysed: 13 (probiotic)/12 (placebo); ITT principle applied
Postrandomisation exclusion: 1 - prednisone prescribed for a flare-up; 1 - personal reasons
Interventions Duration of follow-up: 12 weeks
• Probiotic: patients used 2 sachets per day of 3 grams of the multi species probiotic food supplement
Ecologic 825. The supplement contained nine bacterial strains: Bifidobacterium bifidum W23, Bifi-
dobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei
W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24 and Lac-
tococcus lactis W19, in a concentration of 2.5 x 109 colony forming units per gram for 12 weeks with a
total concentration of 1.5 x 1010 cfu/day
• Placebo for 12 weeks
Mesalazine with a maximum dose of 2.4 g/day was the only medication for UC that was permitted dur-
ing the study
Outcomes Duration of follow-up:
• Relapse. Reported in the discussion section as a flare-up. However, no further description provided
• Quality of life (IBD-Q: 1 to 7, higher score = better quality of life)
Notes Funding source: funding was provided by the Dutch Ministry of Economy Affairs (IPCSFV2900) and Win-
clove Probiotics BV
Declaration of interest: IBvdV is employee of Winclove Probiotics. Winclove develops, researches and
markets probiotic food supplements
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomization scheme was computer generated by Winclove us-




Unclear risk Quote: "It was impossible for research personnel involved with participants to
adjust randomization or discern what product participants were receiving, en-
suring true allocation concealment"





Low risk Quote: "It was impossible for research personnel involved with participants to
adjust randomization or discern what product participants were receiving..."
Comment: study was referred to as double-blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "It was impossible for research personnel involved with participants to
adjust randomization or discern what product participants were receiving..."




Low risk ITT analysis applied
NCT02361957  (Continued)
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Low risk Trial registration is available (NCT02361957) and all prespecified outcomes
were reported




Methods Double-blind, single centre RCT (abstract only)
Setting: not stated
Study period: not stated
Participants Inclusion: within one month of achieving clinical remission of UC following a documented relapse that
required steroids to induce remission. Remission was defined as < 3 bowel movements/day (without
frank/gross blood) out of 7, while oM all steroids
Exclusion: not stated
Age: not stated, however, patients' demographic characteristics were similar across the three treat-
ment groups
Sex: not stated, however, patients' demographic characteristics were similar across the three treat-
ment groups
Site of disease: not stated, however, the extent of colitis which was similar across the groups was leT-
sided in about one-third, limited (proctitis) in one-third and pancolitis in one-third
Use of medication: not stated, however, patients' demographic characteristics were similar across the
three treatment groups
Length of time remission at study entry: not stated
Number randomised (n = 157): not stated (52/52/53?), however, there were similar numbers (52 to 53)
per group
Number analysed: not stated
Postrandomisation exclusion: not stated
Interventions • Probiotic: Lactobacillus salivarius subsp. Salivarius UCC118
• Probiotic: Bifidobacterium infantis 35624
• Placebo
Each intervention was administered as a rehydrated blended yogurt powder (109 daily for one year). A
stable dose of aminosalicylate was the only permitted concomitant medication for colitis
Outcomes Duration of follow-up: 1 year
• Relapse. Defined as < 3 bowel movements per day (without frank/gross blood) out of 7
• Time to relapse
• Adverse events
Notes Funding source: University College Cork
Declaration of interest: not stated
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "a prospective, balanced, randomised, parallel group, double blind,
placebo-controlled trial..."
Comment: not adequately described
Allocation concealment
(selection bias)





Low risk Quote: "...double blind, placebo-controlled trial"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Insufficient information to make a judgement
Selective reporting (re-
porting bias)
High risk Not adequately described; adverse events mentioned but not gone into detail.
Trial registration was available (NCT00510978)





Methods Multicentre, double-blind, randomised, placebo-controlled trial
Setting: Multicentre, Iran, private practices
Study period: not stated
Participants Inclusion criteria: between 15 and 65 years of age, newly diagnosed or recently relapsed UC, based on
clinical, endoscopic, and histological findings and had a mild to moderately active UC according to Tru-
elove and Witts criteria and CAI ≥ 4 and ≤ 12. Additional external participants included in the mainte-
nance of remission phase had to be in remission for less than 3 months.
Exclusion criteria: substantial cardiac, renal or hepatic diseases, severe immunocompromised pa-
tients, existing or intended pregnancy or breastfeeding, regular treatment with NSAID drugs, intestinal
major operation, steroid dependency, known intolerance to sulphate free preparations of mesalazine,
UC exacerbated by infectious colitis, toxic megacolon, use of antibiotic within 14 days prior to first visit
for more than 1 week, use of corticosteroid injection within the last 30 days, use of immunosuppressive
treatment within the last 90 days and use of mesalazine enema or corton enema within the last 14 days
Age (mean ± SD): not stated
Sex (M/F): not stated
Site of disease: not stated
Vejdani 2017 
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Use of concurrent medication: conventional medical treatment for active UC
Treatment before study: not stated
Length of time remission at study entry: less than three months
Number randomised: 14 (probiotic), 15 (placebo)
Number analysed: 14 (probiotic), 15 (placebo)
Postrandomisation exclusion: 2 - lost to follow-up, 1 - concurrent illness, 1 - poor compliance, 1 - tak-
ing antibiotics
Interventions • Probiotic: L Casei strain ATCC PTA-3945, 5 x 105 live active cells. Oral, 1 capsule twice daily
• Placebo: no detail
Participants also received conventional medical treatment for active UC according to the severity and
extension of their disease. Participants with mild proctitis, received mesalazine or sulfasalazine tablets
after remission. In participants with moderate proctitis, mesalazine suppositories were stopped after
remission. The rest of the drugs and their doses were kept unchanged.
Outcomes Duration of follow-up: 4 months
• Relapse (defined as an increase in bowel frequency with blood for at least 1 week. A colonoscopy was
performed and biopsies were taken to confirm relapse)
• Withdrawals
• Serious adverse events
Notes Funding source: not stated
Conflicts of interests: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomisations were done using a random number table with odd
numbers for probiotic and even numbers for placebo; randomisation was
stratified according to the use of mesalazine or sulfasalazine and to the clinical
severity of disease (mild or moderate)"
Comment: use of random number table
Allocation concealment
(selection bias)





Low risk Quote 'Placebos were indistinguishable from the L Casei preparation'
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk The study was reportedly double-blinded however, there is no indication that




Low risk Attrition rate was over 26%, but balanced in both groups
Vejdani 2017  (Continued)
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Selective reporting (re-
porting bias)
High risk Trial registration not available, however, biochemical tests were recorded both
at entry, remission and relapse, but not reported.
Other bias Low risk Quote: "There was not a significant difference between the two groups in fac-
tors such as age, sex, disease duration and extent, smoking, education taken
and clinical activity index”
Comment: baseline characteristics were balanced across groups and there




Methods Double-blinded, multicentre RCT
Setting*: "two participating centers in Denmark"
Study period: June 2004 to March 2006
Participants Inclusion: age ≥ 18 years; established diagnosis of UC leT-sided disease (endoscopic changes distally to
the splenic flexure) - including proctitis; time since relapse > 4 weeks during stable monotherapy with
5-ASA or no medication at all; ≥ 1 relapse within the last year.
Exclusion: pregnancy (postive urine HCG) or breastfeeding; chronic liver or kidney disease; severe
chronic disease of vascular or cardiopulmonary aetiology, malignancies; immunosuppressive disease
or treatment; inflammatory bowel diseases besides UC, malabsorption syndromes, and former surgi-
cal procedures involving the gastrointestinal tract — with the exception of appendectomy. Treatment
with azathioprine, 6-mercaptopurine, biological immunomodifiers, and treatment with steroids within
1 month of entry.
Sex (M/F): 10/22
Age (median/range): 37.5 (23 to 68) years
Site of disease (location from anal valve - cm): 20 (5 to 70) - probiotic/22.5 (5 to 60) - placebo
Use of medication: 24 (5-ASA orally, rectally and both); 1 (salazopyrine)
Length of time remission at study entry: 4 (2 to 9) - probiotic/5 (2 to 11) months - placebo
Number randomised: 20 (probiotics)/12 (placebo)
Number analysed: 20 (probiotics)/12 (placebo)
Postrandomisation exclusion: 1 - pregnancy, however, ITT principle was applied
Interventions • Probiotics: oral preparation containing L acidophilus strain La-5 and B animalis subsp. lactis strain
BB-12
• Placebo. Two capsules taken three times daily for 52 weeks. No other medications for UC were allowed
during the study period
Outcomes Duration of follow-up: 52 weeks
• Number maintaining remission (1 year). Remission - presence of two out of three criteria:
* a simple clinical colitis activity index (SCCAI) score ≤ 4
* endoscopically grade 0-1 (Baron 1964) and/or
* histologically grade 0-1 (Truelove 1956)
• Relapse (reported in the discussion section). Relapse was defined as SCCAI score > 4 and/or endoscop-
ic changes grade 2 to 3
Wildt 2011 
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• Adverse events (flatulence, abdominal bloating and pain; changes in faecal consistency; muscu-
loskeletal - arthralgia, sacroiliitis; various - tiredness, incontinence, stress, oral blisters, eye dryness;
headache, dizziness; influenza, gastroenteritis, cystitis and pneumonia; serious adverse events)
• Serious adverse events
• Withdrawal due to serious adverse events
Notes Funding source: "The study was supported by grants from Chr. Hansen A/S, Hoersholm, Denmark and
by grants received from P. Carl Petersens Foundation and The Danish Crohn Colitis Organisation."
Declaration of interest: "one of the authors (EB) is employed at the laboratory at Chr. Hansen A/S"
*Presumably Gentofte and Hvidovre Hospital, University of Copenhagen Denmark judging by authors'
affiliation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "...randomised in blocks of 6 according to a table-generated randomi-
sation list to receive either Probio-Tec AB-25 (two capsules three times daily,
resulting in a total delivery of 1.5 X 10 11 CFU daily) or to receive placebo (two




Unclear risk Correspondence with author: "At inclusion in the study an enclosed envelope
was drawn from a batch of 6 envelopes - and the randomization revealed."






Low risk Quote: "Placebo medication […] was identical in appearance, size and taste"
Comment: adequate blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Trial was referred to as double-blinded placebo study, however, there were no




Low risk ITT analysis was applied
Selective reporting (re-
porting bias)
Low risk Study protocol available (NCT00268164) and all prespecified outcomes were
reported
Other bias High risk Comment: imbalance in baseline characteristics - there were more partici-
pants receiving medication at inclusion in the intervention group compared to




Methods Double-blind, placebo-controlled, single centre RCT
Setting: Sakura Medical Center, Toho University, Japan
Yasushi 2015 
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Study period: not stated
Participants Inclusion: patients with UC in remission who were receiving treatment on an outpatient basis (UC was
diagnosed in accordance with the diagnostic criteria proposed by the Survey Research Group of In-
tractable Inflammatory Intestinal Disorders/Specified Diseases, Japanese Ministry of Health, Labour
and Welfare); 13 years or older in whom the CAI was maintained at 5 or less while receiving drugs such
as mesalazine, salazosulfapyridine, or steroids, with no change in treatment regimens within 4 weeks
before study entry.
Exclusion: serious cardiac disease, serious renal disease, hypotension (systolic blood pressure, ≤ 80
mmHg), a history of shock during extracorporeal circulation, serious infections such as sepsis or pneu-
monia, or a serum haemoglobin concentration of less than 10 g/dL; newly began treatments such as
leukocytapheresis, granulocyte adsorptive apheresis, or immunosuppressant therapy with drugs such
as 6-mercaptopurine, azathioprine, and cyclosporine to improve symptoms, having milk allergy or a
CAI of 6 or higher; pregnant women
Age (mean ± SD): 43.9 ± 14.8 years*
Sex (M/F): 28/18
Site of disease: 15 (leT colon), 11 (proctosigmoiditis), 20 (total/subtotal)
Use of medication: 24 (pentasa), 19 (salazopyrin), 1 (pentasa + salazopyrin), 2 (nothing)
Length of time remission at study entry: unclear
Number randomised (n = 60): 30 (probiotic)/30 (placebo)
Number analysed: 23 (probiotic)/23 (probiotic)
Postrandomisation exclusions: 14 (7 in each group) - prohibited use of drug and lack of consent
Interventions • Probiotic: Bio-Three - 2 mg Streptococcus faecalis T-110 (lactomin) 10 mg Clostridium butyricum TO-
A, 10 mg Bacillus mesentericus TO-A
• Placebo prepared by substituting equivalent amounts of starch for the probiotic powder
All participants received 3 tablets 3 x daily for 12 months. As concomitant medication, the use of
mesalazine and salazosulfapyridine was unrestricted, but steroids could not be used as remission
maintenance therapy. The use of drugs with similar effects as the study drug, potentially affecting the
evaluation of effectiveness (i.e. other active live microbial preparations, laxatives, etc.) was prohibited
from 1 week before study entry to the completion of the study. In principle, the use of oral antibiotics
was also prohibited, but the use of topical antibiotics other than oral preparations was not particularly
restricted. If a participant received a new treatment in addition to their basic therapy with drugs such
as mesalazine or salazosulfapyridine, relapse was diagnosed, and the study treatment and faecal sam-
ple collection were discontinued.
Outcomes Duration of follow-up: 12 months
• Relapse at 3, 6, 9 and 12 months. Relapse was defined as CAI ≤ 5
• Remission maintenance at 12 months. Remission not absolutely defined
• Serious adverse events
Notes Funding source: This study was supported in part by a grant from the Japan Ministry of Health and
Welfare.
Declaration of interest: partially reported (YY - none, other authors - not reported)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "At the start of the study, 30 outpatients were randomly assigned to the










Low risk Placebo tablets were identical to Bio-Three tablets and could not be distin-
guished from the active preparation on the basis of appearance.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Overall attrition rate was over 20%, but balanced between the two groups
Selective reporting (re-
porting bias)
Low risk Trial registration not available, however, all expected outcomes appear to
have been reported
Other bias Low risk Quote: "After randomization, the baseline characteristics of sex, age, age at
disease onset, disease duration, disease extent, and concomitant treatment
did not differ between the groups"




Methods RCT (abstract only)
Setting: not stated
Study period: not stated
Participants Inclusion: inactive UC and quiescent Crohn's disease*
Exclusion: not stated
Age (mean): 32 years
Sex (M/F): 20/16
Site of disease: not stated
Use of medication: not stated
Length of time remission at study entry: not stated
Number randomised (n = 36): 12 (probiotic)/10 (mesalazine)/14 (probiotic + mesalazine)
Number assessed: 12 (probiotic)/10 (mesalazine)/14 (probiotic + mesalazine)
Zocco 2003 
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Postrandomisation exclusion: none
Interventions • Probiotic alone: Lactobacillus GG 18 X 109 viable bacteria per day (Giflorex, Errekappa, Euroterapic,
SpA, Milan, Italy)
• Probiotic + mesalazine: Lactobacillus GG 18 X 109 viable bacteria and mesalazine 2.4 g per day
• Mesalazine 2.4 g per day
Outcomes Duration of follow-up: 12 months
• Relapse (defined by clinical and endoscopic features. No further details)
• Withdrawal due to adverse events
Notes Funding source: not stated
Declaration of interest: not reported
Data from participants with CD were discarded due to the limited scope of the review.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Not stated
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk All participants appear to have been accounted for
Selective reporting (re-
porting bias)
Unclear risk The study was published as an abstract. Insufficient information to make a
judgement





Methods Open-label, single centre RCT
Setting: Inflammatory Bowel Diseases Centre of the Catholic University, Rome, Italy
Study period: June 2001 to December 2004
Participants Inclusion: UC in clinical (CAI < 4), laboratory and endoscopic remission; time since last relapse: < 12
months
Zocco 2006 
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Exclusion: patients with active disease or complications, severe accompanying illness or major colonic
surgery, gastrointestinal infections, serious concomitant diseases (renal or hepatic failure, severe hy-
pertension), diabetes mellitus, immunosuppressive treatment being administered currently or in the
month before enrolment, mesalazine intolerance, and pregnant or lactating woman
Age (mean ± SD): 33 ± 5.8 years*
Sex (M/F): 104/83
Site of disease: 35 (proctosigmoiditis), 25 (leT colon), 12 (total/subtotal)
Use of medication: not stated
Length of time remission at study entry: ≤ 4 weeks in 12% (probiotic)/11% (probiotic +
mesalazine)/10% (mesalazine); ≤ 3 months in 26% (probiotic)/25% (probiotic +mesalazine)/26%
(mesalazine)
Number randomised (n = 187): 65 (probiotic)/62 (probiotic + mesalazine)/60 (mesalazine)
Number analysed: 65 (probiotic)/62 (probiotic + mesalazine)/60 (mesalazine)
Postrandomisation exclusion: none (premature discontinuation of the study for reasons other than
relapse did not occur)
Interventions • Probiotic: Lactobacillus GG treatment 18 x 109 viable bacteria/day divided into two oral administra-
tions
• Mesalazine 800 mg tablets (mesalazine Errekappa, Euroterapici SpA), three tablets (2400 mg) daily
• Probiotic + mesalazine: Lactobacillus GG 118 x 109 viable bacteria/day plus mesalazine 2400 mg daily
Participants were treated for 12 months. Treatment was interrupted in case of disease relapse, occur-
rence of side effects, poor compliance and inability to attend follow-up visit. Oral or rectal treatment
with antibiotic or steroid medications, apart from the study drugs, was not allowed during the trial. Full
clinical evaluation with symptoms assessment and physical examination was performed at baseline
and every 3 months for all the 12-month study period.
Outcomes Duration of follow-up: 12 months
• Relapse (6 and 12 months). Relapse defined as the appearance of UC symptoms or an increase in CAI
to more than 4 points.
• Maintenance of remission at 6 and 12 months
• Serious adverse events
Notes Funding source: no external funding
Declaration of interests: not reported
*Reported for the three intervention groups and pooled using an online calculator (www.statsto-
do.com/CombineMeansSDs_Pgm.php)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated
Zocco 2006  (Continued)
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High risk The study was an open-label study
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk All participants were accounted for
Selective reporting (re-
porting bias)
Low risk Trial registration not available, however, all participants were accounted for
Other bias Low risk Quote: "Demographic and prestudy clinical characteristics did not differ signif-
icantly among the three groups"
Comment: no other apparent biases
Zocco 2006  (Continued)
5-ASA: 5-aminosalicylic acid; CAI: colitis activity Index; CD: crohn's disease; CFU: colony forming units; CRP; C-reactive protein; DAI: disease
activity index; FCAL: fecal calprotectin; GI: gastrointestinal HCG: human chorionic gonadotropin; IBD: inflammatory bowel disease; IBD-
Q: inflammatory bowel disease questionnaire; ITT: intention to treat IV: intervention; NSAID: non steroidal ant-inflammatory drugs; QoL;
quality of life; RCT: randomised controlled trial; SCCAI: simple clinical colitis activity index; SD: standard deviation; UC: ulcerative colitis
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ahmed 2013 Insufficient duration of follow-up, i.e. less than 3 months; (quote): "if this could be altered with one
months treatment with synbiotics"
Ballini 2019 Wrong patient population and not maintenance study
Bamba 2002 Wrong intervention, i.e. uses prebiotic; (quote): "A new prebiotic from germinated barley..."
Cui 2004 Insufficient duration of follow-up; (quote): "the patients were evaluated ....after 2 mo of treat-
ment..."
Do 2010 Wrong study design, i.e. review article
Faubion 2000 Wrong study design, i.e. commentary piece
Folwaczny 2000 Wrong study design, i.e. not randomised
Fujimori 2009 Wrong patient population, i.e. patients were not in remission, so not maintenance trial
Henker 2008 Wrong study design, i.e. not randomised
IRCT20120415009475N5 Wrong study type
Ishikawa 2002 Insufficient information: emailed author for clarification, no reply
Ishikawa 2011 Wrong patient population: data from patients in remission presented together with those not in re-
mission, unable to differentiate data
Probiotics for maintenance of remission in ulcerative colitis (Review)
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Study Reason for exclusion
Li 2013 Wrong patient population: patients not in remission, so not maintenance trial
Liu 2014 Wrong patient population: translated from Chinese and confirmed not maintenance study
Miele 2009 Wrong patient population: patients not in remission, so not maintenance study
NCT00268164 Insufficinet information: university replied 26 February 2018 - no access to full paper
NCT00374725 Insufficient information: no reply from author - emailed 15 January 2018
NCT00803829 Insufficient information: author passed away - no access to full paper
NCT00951548 Insufficient information: emailed author for classification on 15 January 2018, replied and con-
firmed not maintenance trial
NCT01772615 Wrong patient population: author replied with full paper - patients not in remission so not mainte-
nance study
Palumbo 2016 Wrong patient population: patients being induced, so not maintenance study
Pelech 1998 Insufficient information: emailed author for classification, no reply
Rembacken 1999 Includes both an induction and maintenance phase, however, participants were only randomised
for induction. The maintenance phase was an observational study.
Rohatgi 2015 Wrong patient population: patient cohort have microscopic colitis so not ulcerative colitis study
Sanchez-Morales 2019 Induction study
Shadnoush 2013 Wrong patient population: study uses patients with inflammatory bowel disease - does not differ-
entiate between ulcerative colitis and Crohn's
Solovyeva 2014 Wrong patient population: patients being induced, so not maintenance trial
Tursi 2010 Wrong patient population: patients being induced, so not maintenance trial
Venturi 1999 Wrong study design: this study was not a randomised controlled trial
Zhang 2018a Induction study
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods RCT, single centre
Setting: The First Affiliated Hospital of Fujian Medical University
Study duration: January 2015 to June 2016
Participants 40 with IBD randomised (19 control group, 21 observation group)
UC total: 31, CD total: 9; UC control 15, CD IV 4; CD control 4, CD IV 5
Fan 2019 
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Inclusion: confirmed IBD diagnosis with mild to moderate symptoms as per the current standards
in China; no previous probiotic treatment; no allergy to drugs used in the present study; cognisance
of the purpose of the present study and willingness to sign an informed consent
Exclusion: severe heart, liver, kidney and other systemic diseases; pregnancy or lactation; unre-
sponsive to medical treatment and with complications; immune system disorders
Sex (M/F): 10/9 control group; 10/11 observation group
Age (mean +/- SD): 39.97 +/- 8.68 control group; 42.56 +/- 7.58 observation group
Site of disease: not specified
Use of medication: not specified
Length of time remission at study entry: not specified
Number randomised: 40
Number assessed: not specified
Postrandomisation exclusion: not specified
Follow-up: 40 days
Interventions IV: pentasa (mesalazine extended action tablet) as in the control regimen + probiotics (2 tablets Bi-
fico once and three times/day + "a largely liquid-based high nutrition diet"
Control: 1 to 2 pentasa tablets once and three times/day and a maintenance dose of 1 tablet once
and three times/day




Notes Mixed: contacted author for UC data
This work was supported by the Fujian Province Natural Science Fund Project





Setting: Chunan County First People's Hospital and Taizhou Hospital
Study duration: February 2016 to September 2017
Participants 84 patients with UC (42 control, 42 IV)
Control: 18 mild, 24 moderate; IV: 19 mild, 23 moderate
Inclusion: met the relevant diagnostic criteria for UC, confirmed by colonoscopy, barium enema,
etc; course of disease ≥ 4 weeks; accompanied by persistent or recurrent diarrhoea, haemorrhag-
ic stool with abdominal pain, acute aftermath etc; age ≥ 18 years; volunteer to participate in this
study and sign informed consent
Exclusion: those with allergies; combined with infectious colitis such as amoebiasis, bacterial dis-
ease, intestinal tuberculosis, chronic schistosomiasis; severe intestinal perforation, intestinal ob-
Fang 2018 
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struction, toxic colonic dilatation etc; people with unconsciousness, serious insufficiency of impor-
tant organs such as heart and kidney; people with radiation colitis, ischaemic colitis, Crohn's dis-
ease, mental illnesses, history of drug and alcohol abuse; pregnant, lactating women
Sex (M/F): 26/16 control; 28/14 IV
Age: 45.12 +/- 6.21 control; 45.13 +/- 6.2 IV
Site of disease: control: whole colon 15, right half colon 19, leT half colon 8; IV: whole colon 16,
right half colon 17, leT half colon 9
Use of medication: not specified
Length of time remission at study entry: not specified
Number randomised: 84
Number assessed: not specified
Postrandomisation exclusion: not specified
Follow-up: 2 months
Interventions IV: mesalazine + gold bifid
Control: mesalazine only
Outcomes • Inflammation markers (IL-10, TNF-α, IL-18, sIL-2R)
• Lesion activity scores (modified Mayo scores)
• Clinical efficacy
• Anorectal motility
Notes Disease activity to be clarified. 95 versus 76% effective rate
Main article in Chinese. Google translate was used for the translation.




Methods RCT, single centre
Study duration: May 2014 to February 2018
Setting: Bai'an Affiliation Sanxia Central Hospital of Chongqing
Participants Abstract: 120 UC patients (control 60, IV 60)
Main text: 360 UC patients (control 180, IV 180) ???
Inclusion: not specified
Exclusion: not specified
Sex (M/F): 81/99 control; 90/90 IV
Age (mean +/- SD): 41.5 +/- 8.3 control; 42.2 +/- 9.4 IV
Site of disease: not specified
Use of medication: not specified
Huang 2018 
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Length of time remission at study entry: not specified
Number randomised: 120 or 360
Number assessed: not stated
Postrandomisation exclusion: not stated
Follow-up: 8 weeks
Interventions Control: mesalazine only
IV: mesalazine + bifid triple viable capsules enteric-coated tablet of mesalazine (Sunflower Group
Jiamusi Luling Pharmaceutical Co, Ltd, 0.25 g/tablet, batch No.: 13001830), four tablets oral admin-
istration before meal, 3 times/day. Those in the research group would additionally take two bifid
triple viable capsules (Jincheng Haisi Pharmaceutical Co, Ltd, 0.21 g/capsule,
Batch No.: 13012365) prior to meal, 3 times/day
Outcomes • Evaluation of clinical efficacy
• DAI of UC
• Score of clinical symptoms
• Changes in inflammatory factors (TNF-α, IL-8 and IL-10)
• Adverse reactions
Notes Unclear whether active or inactive UC - emailed authors. Effectiveness rate = 90 versus 72%




Methods RCT, single centre
Setting: Department of Gastroenterology, Anji County People's Hospital of Huzhou City
Study duration: August 2014 to November 2016
Participants 86 UC patients (43 control, 43 IV)
Inclusion criteria: all who met the diagnosis of ulcerative colitis in the "Consensus Opinions on the
Diagnosis and Treatment of Inflammatory Bowel Diseases in China" formulated by the Collabora-
tive Group of Inflammatory Bowel Diseases of the Chinese Medical Association Gastroenterology
Branch Criterion, with typical clinical manifestations (diarrhoea, mucus, pus, blood, stool, etc.) and
colonoscopy (continuous, diffuse distribution of ulcer surface); Patients agreed to the study and
signed informed consent
Exclusion: those who used contraindications to the study; those who had poor compliance during
treatment; other reasons were not suitable for inclusion in the study
Sex (M/F): IV: 14/27; control: 17/24
Age (mean +/- SD): IV: 47.1 +/- 4.9; control: 47.3 +/- 6.2
Site of disease: not specified
Use of medication: not specified
Length of time remission at study entry: not specified
Number randomised: 86
Shi 2018 
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Number assessed: not specified
Postrandomisation exclusion: not specified
Follow-up: treatment 2 months + 6 months
Interventions IV: Bacillus subtilis and Enterococcus faecium + mesalazine
Control: mesalazine only
Mesalazine enteric-coated tablets (Sunflower Pharmacy, Chinese Medicine Standard: H19980148,
(specification: 0.25 g/tablet), oral, 1 g/time, 6 h/time; the observation group was combined with
the Bacillus subtilis double live enteric-coated capsules (trade name: Mei Changan, Beijing Han-
mei Pharmaceutical Co, Ltd. based on the control group). Company, National Medicine Standard:
S20030087, specification: 250 mg/capsule), 500 mg, orally, 3 times/day; two groups of patients
were continuously taking medication for 2 months.
Outcomes • Inflammation markers (IL-6, IL-8, IL-10, TNF-α, MDA, SOD, COX-2, NF-κΒ)
• Clinical curative effect
• Time to symptom relief
• Rachmitewitz and Sutherland scores
Notes Disease activity to be clarified. 93% versus 76% effective rate
Article in Chinese. Google Translate was used for the translation.




Methods RCT, single centre, prospective, open-label
Study duration: May 2015 to December 2016
Participants 45 IBD patients (25 IV, 20 control)
UC = 15, CD = 10
Inclusion/exclusion: "Patients with IBD participated in the study. In the trial, CD Activity Index for
CD and Truelove-Witts scoring systems for UC were used for disease assessment scores. If the score
was <450, patients with CD were admitted to the study. If the score was higher, patients with UC
were not admitted to the study. Volunteers also had to be >18 years old. Patients with alcohol con-
sumption > 20 g/day, allergies or intolerance to milk, antibiotic treatment within the last 1 month,
column or bowel operation history up to 3 months before the start of the study, and the presence
of active infection within 1 month prior to the start of the study or during the study were exclud-
ed from the study. In addition, if a patient requested to leave on his/her own will, or if kefir was not
consumed continuously for 2 weeks, the trial protocol was assessed and was not approved."
Sex (M/F): IV: total 13/12, UC 9/6, CD: 4/6, control: total 10/10, UC: 4/6, CD: 6/4
Age (median): IV: 33, control: 43
Site of disease: IV: UC colon 15, CD colon 1, Ileum 6, colon + Ileum 3; control: UC colon 10, CD Ileum
10
Use of medication: not specified
Length of time remission at study entry: not specified
Number randomised: 45?
Yilmaz 2019 
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Number assessed: 45
Postrandomisation exclusion: either 0 or 3. Authors mention 3 patients leT the trial willingly,
however participant and completers number are the same (n = 45)
Follow-up: 4 weeks
Interventions IV: 400 mL/day kefir x 2 day
Control: ???
"The control group did not consume placebo because it was not possible to prepare a control prod-
uct with a similar flavor, texture, and taste as those of kefir. Ayran and yogurt were similar to kefir,
but they also have Lactobacillus and can affect the microbiota results."
Outcomes • Symptoms diary questionnaire
• Effects on Lactobacillus flora and their biochemical properties
Notes Disease activity not clear. 96% versus 85% effective rate




Methods RCT, single centre
Setting: Department of Gastroenterology, Longyou County People's Hospital, Luzhou, Zhejiang
Province
Study duration: October 2016 to November 2017
Participants 110 UC patients (55 control (38 UC, 17 CD); 55 observation (36 UC, 19 CD))
Inclusion: in accordance with the diagnostic criteria of the "Consensus on the diagnosis and treat-
ment of inflammatory bowel disease in China" formulated by the Chinese Medical Association; no
significant abnormalities in liver and kidney function; no other severe chronic diseases; informed
consent
Exclusion: severe liver and kidney diseases; intestinal diseases such as intestinal tuberculosis,
Crohn's disease, intestinal tumours; hormones, 5-aminosalicylic acid, and intestinal probiotics for
nearly 4 weeks; patients taking other drugs; patients who are allergic to drugs such as mesalazine,
Bifidobacterium quadruplex, etc.; pregnant and lactating women; patients with mental illness; pa-
tients who do not co-operate with treatment; younger than 18 years old
Sex (M/F): IV 29/26; control 32/23
Age (mean +/- SD): IV: 44.6 +/- 5.8; control 45.3 +/- 5.5
Site of disease: not specified
Use of medication: not specified
Length of time remission at study entry: not specified
Number randomised: 110
Number assessed: not specified
Postrandomisation exclusion: not specified
Follow-up: 2 months
Zhang 2018b 
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Interventions IV: Bifidobacterium quadruplex bacteria tablets + mesalazine
Control: mesalazine
Both groups were given mesalazine enteric-coated tablets (trade name: Huidi, Manufacturer: Sun-
flower Pharmaceutical Group Jiamusi Luling Pharmaceutical Co, Ltd, National Medicine Standard
H19980148, 0.25 g/tablet), oral, 1 g/3 times/day. The observation group was given a Bifidobac-
terium quadruple live bacteria tablets (brand name: Siliankang, manufacturer: Hangzhou Longda
Xinke Biopharmaceutical Co, Ltd, National Medicine Standard)
S20060010, 0.5 g/tablet), oral, 1.5 g/3 times/day
Outcomes • Total effective rate
• Lipid peroxidation injury indexes
• Inflammatory factors
• Peripheral T cell subsets
• Adverse reactions
Notes Article in Chinese. Google Translate was used for the translation.
Funding and conflict of interest were not discussed in the article.
Zhang 2018b  (Continued)
CD: crohn's disease; COX-2: cyclooxygenase-2; DAI: disease activity index; IBD: inflammatory bowel disease; IL: interleukin; IV: intervention;
MDA: malondialdehyde; NF-κβ: nuclear factor kappa beta; RCT; randomised controlled trial; sIL-2R: soluble interleukin 2 receptor; SOD:
superoxide dismutase; TNF- α: tumor necrosis factor alpha; UC: ulcerative colitis
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title PRObiotic VSL#3® for maintenance of clinical and endoscopic REMission in Ulcerative Colitis
(PROREM UC)
Methods RCT, double-blind, parallel assignment
Participants 39 UC participants
Interventions • Group A: 13 participants will receive mesalamine 2.4 g/day in once daily administration plus
VSL#3® 450 billion sachet, two sachets per day for 12 months (900 billion of bacteria per day)
• Group B: 13 participants will receive mesalamine 2.4 g/day in once daily administration plus
VSL#3® 450 billion sachet, two sachets twice a day (1800 billion of bacteria per day) for 12 months
• Group C: 13 patients will receive mesalamine 2.4 g/day in once daily administration plus placebo
for 12 months
Outcomes • To characterise the efficacy of VSL#3® plus standard therapy (5-ASA) in maintaining clinical and
endoscopic remission in patients with UC in remission (time frame: 12 months)
• Proportion of subjects in clinical and endoscopic remission at 12 months, as defined by Total Mayo
Score ≤ 2 with no individual subscore > 1 and rectal bleed subscore of 0
Starting date April 2017
Contact information Antonino Amato clinicaltrialcentre@policlinicogemelli.it
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Trial name or title Probiotic Treatment of Ulcerative Colitis with Trichuris Suis Ova (PROCTO)
Methods RCT, parallel assignment, double-blind, comparative, exploratory phase II proof of concept trial
Participants 120 UC participants
Interventions IV: trichuris suis ova
Control: placebo
Outcomes Primary outcome measures
• Response (full Mayo) (time frame: 24 weeks). The proportion of TSO participants, compared with
placebo participants (i.e. a proportional difference), who obtain a reduction of 3 or more full Mayo
score steps between the baseline visit and the end of trial visit (week 24). The full Mayo score
(range 0-12) is the sum of 4 clinical scores (stool frequency, rectal bleeding, findings on endoscopy,
physician's global assessment) each scored with a value 0 (normal), 1, 2, or 3 (worst).
Secondary outcome measures
• Remission (full Mayo) (time frame: 24 weeks). Proportion of TSO participants, compared with
placebo participants (i.e.. a proportional difference), who obtain a full Mayo score ≤ 2 at the end
of trial visit (week 24) (remission).
• Reduction in use of steroid (time frame: 24 weeks). Mean value of total accumulated sum of mil-
ligram oral and rectal glucocorticosteroids taken by TSO participants during the trial compared
with the corresponding mean value among placebo participants.
Starting date May 2018
Contact information Contact: Michelle V Prosberg, MD,
michelle.vernstroem.prosberg@regionh.dk
Contact: Andreas M Petersen, MD, Ph.D
andreas.munk.petersen@regionh.dk




Trial name or title Lactobacillus reuteri ATCC PTA 4659 in ulcerative colitis (COLUS)
Methods RCT, triple-blind, parallel assignment
Participants 40 UC patients
Interventions Lactobacillus reuteri versus placebo
Outcomes Primary outcome measures
• Rectal bleeding with Mayo score ≥ 5 (time frame: 12 months). Rectal bleeding as sign of increased
inflammatory activity as determined by the Mayor Clinic Score for evaluation of disease activity
in ulcerative colitis
Secondary outcome measures
• Increased faecal calprotectin (time frame: 12 months)
NCT03798210 
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• Gut inflammatory biomarker
• Increased CRP (time frame: 12 months)
• General inflammatory biomarker
Other outcome measures
• Serum zonulin (time frame: 12 months)
• Gut permeability biomarker. Gut permeability (time frame: 12 months). Recovery of sugar mole-
cules in urine as marker of increased permeability
Starting date January 2017
Contact information Contact: Per M Hellström, Prof +46 70 3727423 per.hellstrom@medsci.uu.se; Peter Benno, MD, PhD
+46 70 5795554 peter.benno@endoskopienheten.se




Trial name or title Multistrain probiotics reduces UC depression and anxiety scores
Methods RCT, double-blind, parallel assignment
Participants 60 UC patients
Interventions IV: multistrain probiotic product (DSF)
Control: placebo
Outcomes Primary outcome measures
• Reduction of anxiety and depression scores (time frame: 0 week, 8 weeks, 12 weeks, 16 weeks)
• Reduction of anxiety and depression scores (with points as standard units) using HADS at 8 weeks
and 16 weeks after randomised treatment
Secondary outcome measures
• Clinical response (time frame: 4 weeks, 8 weeks, 12 weeks, 16 weeks) measured by a ≥ 1.5(3) points
reduction in Simple Clinical Colitis Activity Index score at week 8 and 16
• Clinical remission (time frame: 4 weeks, 8 weeks, 12 weeks, 16 weeks) measured by Simple Clinical
Colitis Activity Index score ≤ 5(2) points at week 8 and 16
• Endoscopic remission/response (time frame: 0 week, 16 weeks) measured by a Mayo endoscopic
subscore of < 1 point, or at least a 1-point reduction from baseline in the endoscopy subscore at
week 16
• Changes in faecal-associated microbiota following probiotic therapy (time frame: 0 week, 16
weeks). Changes in faecal-associated microbiota using 16S ribosomal RNA sequencing and
changes in the metabolomic profile of the faeces following probiotic therapy (at baseline and 16
weeks) will be assessed, stratified by both change in Simple Clinical Colitis Activity Index score
following probiotic therapy and randomization
• Identification of potential stressors (time frame: 0 weeks, 16 weeks). Participants will be asked to
complete a modified practical and family problem list to identify 13 potential stressors
Adverse events (time frame: 4 weeks, 8 weeks, 12 weeks, 16 weeks). Adverse events were assessed
at weeks 8 and 16 by participant survey.
Starting date October 2019
NCT04006977 
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Contact information Prof Jie Liang liangjie@fmmu.edu.cn
Notes Sponsors and collaborators: Xijing Hospital of Digestive Diseases, MENDES SA
NCT04006977  (Continued)
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Comparison 1.   Probiotics versus placebo





Statistical method Effect size
1 Clinical relapse 4 361 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.63, 1.18]
2 Maintenance of clinical remission 2 141 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.98, 1.37]
3 Serious adverse events 4 351 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Withdrawal due to adverse events 2 113 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]





Analysis 1.1.   Comparison 1 Probiotics versus placebo, Outcome 1 Clinical relapse.
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bjarnason 2019 0/40 4/41 1.15% 0.11[0.01,2.05]
Matsuoka 2018 55/98 58/97 68.21% 0.94[0.74,1.19]
NCT02361957 0/13 2/12 1.11% 0.19[0.01,3.52]
Yasushi 2015 14/30 17/30 29.52% 0.82[0.5,1.35]
   
Total (95% CI) 181 180 100% 0.87[0.63,1.18]
Total events: 69 (Probiotics), 81 (Placebo)  
Heterogeneity: Tau2=0.02; Chi2=3.6, df=3(P=0.31); I2=16.66%  
Test for overall effect: Z=0.91(P=0.36)  
Favours probiotics 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Probiotics versus placebo, Outcome 2 Maintenance of clinical remission.
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bjarnason 2019 40/40 37/41 75.53% 1.11[0.99,1.24]
Favours placebo 1000.01 100.1 1 Favours probiotics
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Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Yasushi 2015 16/30 12/30 24.47% 1.33[0.77,2.31]
   
Total (95% CI) 70 71 100% 1.16[0.98,1.37]
Total events: 56 (Probiotics), 49 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1, df=1(P=0.32); I2=0%  
Test for overall effect: Z=1.77(P=0.08)  
Favours placebo 1000.01 100.1 1 Favours probiotics
 
 
Analysis 1.3.   Comparison 1 Probiotics versus placebo, Outcome 3 Serious adverse events.
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bjarnason 2019 0/40 0/41   Not estimable
Matsuoka 2018 0/97 0/95   Not estimable
Wildt 2011 0/20 0/12   Not estimable
Yasushi 2015 0/23 0/23   Not estimable
   
Total (95% CI) 180 171 Not estimable
Total events: 0 (Probiotics), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours probiotics 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Probiotics versus placebo, Outcome 4 Withdrawal due to adverse events.
Study or subgroup Probiotics Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bjarnason 2019 0/40 0/41   Not estimable
Wildt 2011 0/20 0/12   Not estimable
   
Total (95% CI) 60 53 Not estimable
Total events: 0 (Probiotics), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours probiotic 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Probiotics versus placebo, Outcome 5 Health-related quality of life.
Study or subgroup Probiotics Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
NCT02361957 13 3.5 (0.7) 12 4.2 (1.5) 100% -0.7[-1.63,0.23]
   
Total *** 13   12   100% -0.7[-1.63,0.23]
Heterogeneity: Not applicable  
Favours placebo 10050-100 -50 0 Favours probiotics
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Study or subgroup Probiotics Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=1.48(P=0.14)  
Favours placebo 10050-100 -50 0 Favours probiotics
 
 
Comparison 2.   Probiotics versus 5-aminosalicylic acid (5-ASA) (mesalazine)





Statistical method Effect size
1 Clinical relapse 2 452 Risk Ratio (M-H, Random, 95%
CI)
1.01 [0.84, 1.22]
2 Maintenance of clinical remission 1 125 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.90, 1.25]
3 Serious adverse events 1 327 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.41, 3.46]
4 Withdrawal due to adverse events 1 222 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.46, 2.25]





Analysis 2.1.   Comparison 2 Probiotics versus 5-aminosalicylic
acid (5-ASA) (mesalazine), Outcome 1 Clinical relapse.
Study or subgroup Probiotics 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kruis 2004 92/162 91/165 94.02% 1.03[0.85,1.25]
Zocco 2006 10/65 12/60 5.98% 0.77[0.36,1.65]
   
Total (95% CI) 227 225 100% 1.01[0.84,1.22]
Total events: 102 (Probiotics), 103 (5-ASA)  
Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.12(P=0.9)  
Favours probiotics 100.1 50.2 20.5 1 Favours 5-ASA
 
 
Analysis 2.2.   Comparison 2 Probiotics versus 5-aminosalicylic acid (5-
ASA) (mesalazine), Outcome 2 Maintenance of clinical remission.
Study or subgroup Probiotics 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Zocco 2006 55/65 48/60 100% 1.06[0.9,1.25]
   
Total (95% CI) 65 60 100% 1.06[0.9,1.25]
Total events: 55 (Probiotics), 48 (5-ASA)  
Heterogeneity: Not applicable  
Favours 5-ASA 1000.01 100.1 1 Favours probiotics
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Study or subgroup Probiotics 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=0.67(P=0.5)  
Favours 5-ASA 1000.01 100.1 1 Favours probiotics
 
 
Analysis 2.3.   Comparison 2 Probiotics versus 5-aminosalicylic
acid (5-ASA) (mesalazine), Outcome 3 Serious adverse events.
Study or subgroup Probiotics 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Kruis 2004 7/162 6/165 100% 1.19[0.41,3.46]
   
Total (95% CI) 162 165 100% 1.19[0.41,3.46]
Total events: 7 (Probiotics), 6 (5-ASA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
Favours probiotics 1000.01 100.1 1 Favours 5-ASA
 
 
Analysis 2.4.   Comparison 2 Probiotics versus 5-aminosalicylic acid (5-
ASA) (mesalazine), Outcome 4 Withdrawal due to adverse events.
Study or subgroup Probiotics 5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Kruis 2004 11/110 11/112 100% 1.02[0.46,2.25]
   
Total (95% CI) 110 112 100% 1.02[0.46,2.25]
Total events: 11 (Probiotics), 11 (5-ASA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.96)  
Favours probiotics 1000.01 100.1 1 Favours 5-ASA
 
 
Analysis 2.5.   Comparison 2 Probiotics versus 5-aminosalicylic acid
(5-ASA) (mesalazine), Outcome 5 Health-related quality of life.
Study or subgroup Probiotics 5-ASA Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Kruis 2004 110 24.3 (5.2) 112 25.1 (3.9) 100% -0.8[-2.01,0.41]
   
Total *** 110   112   100% -0.8[-2.01,0.41]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.3(P=0.2)  
Favours probiotics 10050-100 -50 0 Favours 5-ASA
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Comparison 3.   Probiotic + 5-aminosalicylic acid (5-ASA) (mesalazine) versus 5-ASA (mesalazine)





Statistical method Effect size
1 Clinical relapse 2 242 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.66, 1.87]
2 Maintenance of clinical remission 1 122 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.89, 1.24]
3 Withdrawal due to serious ad-
verse events
2 127 Risk Ratio (M-H, Fixed, 95% CI) 5.29 [0.26, 107.63]
 
 
Analysis 3.1.   Comparison 3 Probiotic + 5-aminosalicylic acid (5-ASA)
(mesalazine) versus 5-ASA (mesalazine), Outcome 1 Clinical relapse.
Study or subgroup Probiot-
ic + 5-ASA
5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Kruis 1997 18/60 13/60 58.78% 1.38[0.75,2.57]
Zocco 2006 10/62 12/60 41.22% 0.81[0.38,1.73]
   
Total (95% CI) 122 120 100% 1.11[0.66,1.87]
Total events: 28 (Probiotic + 5-ASA), 25 (5-ASA)  
Heterogeneity: Tau2=0.02; Chi2=1.17, df=1(P=0.28); I2=14.7%  
Test for overall effect: Z=0.39(P=0.7)  
Favours probiotics +5-ASA 1000.01 100.1 1 Favours 5-ASA
 
 
Analysis 3.2.   Comparison 3 Probiotic + 5-aminosalicylic acid (5-ASA) (mesalazine)
versus 5-ASA (mesalazine), Outcome 2 Maintenance of clinical remission.
Study or subgroup Probiot-
ic + 5-ASA
5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Zocco 2006 52/62 48/60 100% 1.05[0.89,1.24]
   
Total (95% CI) 62 60 100% 1.05[0.89,1.24]
Total events: 52 (Probiotic + 5-ASA), 48 (5-ASA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
Favours 5-ASA 20.5 1.50.7 1 Favours probiotic + 5-ASA
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Analysis 3.3.   Comparison 3 Probiotic + 5-aminosalicylic acid (5-ASA) (mesalazine)
versus 5-ASA (mesalazine), Outcome 3 Withdrawal due to serious adverse events.
Study or subgroup Probiot-
ic + 5-ASA
5-ASA Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Kruis 1997 2/50 0/53 100% 5.29[0.26,107.63]
Zocco 2003 0/14 0/10   Not estimable
   
Total (95% CI) 64 63 100% 5.29[0.26,107.63]
Total events: 2 (Probiotic + 5-ASA), 0 (5-ASA)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
Favours probiotic + 5-ASA 1000.01 100.1 1 Favours 5-ASA
 
 
A D D I T I O N A L   T A B L E S
 



























30% versus 28% NR 77% ver-
sus 90%
NR NR NR
Kruis 1997 8/50 versus 6/53;
18/60 versus 13/60
CAI > 4 NR NR NR 2/50 ver-
sus 1/53
Kruis 2004 40/110 versus 38/112;
92/162 versus 91/165
The presence of all of the follow-
ing: CAI > 6 (or an increase in CAI of
at least 3 points with CAI = 4 being
exceeded at the same time); endo-


















The persistence of a rectal bleeding
score of ≥ 2 on Sutherland DAI score
for 3 consecutive days and/or initia-
tion of remission induction therapy
for worsening of UC
Reported
P = 0.643




NR Defined as < 3 bowel movements per
day (without frank/gross blood) out
of 7
NR NR NR NR
Table 1.   Outcome data table 
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An increase in bowel frequency
with blood for at least 1 week. A
colonoscopy was performed and
biopsies were taken to confirm re-
lapse
NR NR 0 NR





















2/12 versus 2/10 versus
4/14
Defined by clinical and endoscopic
features










The appearance of UC symptoms











Table 1.   Outcome data table  (Continued)
*Serious adverse events which occurred were reportedly not related to the intervention (avascular necrosis of bilateral femoral head and
pulmonary thromboembolism)





Clinical relapse RR 0.85, 95% CI 0.68 to 1.05 RR 0.87, 95% CI 0.63 to 1.18
Maintenace of clinical remission RR 1.16, 95% CI 0.98 to 1.37 RR 1.11, 95% CI 0.99 to 1.24
Probiotics versus 5-ASA
Clinical relapse RR 1.00, 95% CI 0.83 to 1.21 RR 1.01, 95% CI 0.84 to 1.22
Maintenace of clinical remission RR 1.06, 95% CI 0.90 to 1.25 RR 1.06, 95% CI 0.90 to 1.25
Probiotics + 5-ASA versus 5-ASA
Clinical relapse RR 1.10, 95% CI 0.69 to 1.78 RR 1.11, 95% CI 0.66 to 1.87
Maintenance of clinical remission RR 1.05, 95% CI 0.89 to 1.24 RR 1.05, 95% CI 0.89 to 1.24
Table 2.   Sensitivity analysis 
5-ASA: 5-aminosalicylic acid; CI: confidence interval; RR: risk ratio
 
 
Probiotics for maintenance of remission in ulcerative colitis (Review)









Cochrane Database of Systematic Reviews
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8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.




14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. exp ulcerative colitis/
20. colitis.mp.
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33. (bifidus or bifidobacter*).tw.














48. (beneficial adj3 bacter*).tw.
49. (Escherichia coli or "E. coli").tw.
50. Yeast.tw.
51. (fungus or fungi).tw.
52. (VSL# 3 or VSL 3).tw.
53. Or/25-52









8. (singl$ adj blind$).tw.
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45.(Escherichia coli or "E. coli").tw.
46.Yeast.tw.
47.(fungus or fungi).tw.
48.(VSL# 3 or VSL 3).tw.
49.Or/21-48
50.14 and 20 and 49
Cochrane CENTRAL
#1 MeSH descriptor: [Probiotics] explode all trees
#2 MeSH descriptor: [Synbiotics] explode all trees
#3 probiotic*
#4 synbiotic*
#5 MeSH descriptor: [Lactobacillus] explode all trees
#6 lactobacill*
#7 bacill*
#8 MeSH descriptor: [Bifidobacterium] explode all trees
#9 (bifidus or bifidobacter*)
#10 MeSH descriptor: [Streptococcus thermophilus] explode all trees
#11 streptococcus thermophilus
#12 streptococc*
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#13 MeSH descriptor: [Lactococcus] explode all tree
#14 lactococc*
#15 MeSH descriptor: [Bacillus subtilis] explode all trees
#16 bacillus subtilis
#17 MeSH descriptor: [Enterococcus] explode all trees
#18 enterococcus faec*





#24 (Escherichia coli or "E. coli").tw.
#25 Yeast.tw.
#26 (fungus or fungi).tw.
#27 Or/ #1- #26
#28 MeSH: [Ulcerative colitis] explode all trees
#29 UC
#30 Inflammatory bowel disease
#31 IBD
#32 #28 or #29 #30 and #31
#33 #27 and #32
The Cochrane IBD/FBD Review Specialised Trials Register
1. Probiotics and Inflammatory bowel disease
2. Probiotics and Ulcerative colitis
3. Synbiotics and Inflammatory bowel disease
4. Synbiotics and Ulcerative colitis
CINAHL
1. (TI probiotic* or AB probiotic*) OR (TI synbiotic* or AB synbiotic*) OR (TI probiotics* or AB probiotics*) OR (TI lactobacill* or AB
lactobacill*) OR (TI bacill* or AB bacill*) OR (TI bifidobacter* or AB bifidobacter*) OR (TI bifidus* or AB bifidus*) OR (TI streptococc* or AB
streptococc*) OR (TI lactococc* or AB lactococc*) OR (TI enterococcus* or AB enterococcus*) OR (TI saccharomyc* or AB saccharomyc*) OR
(TI leuconostoc* or AB leuconostoc*) OR (TI pediococc* or AB pediococc*) OR (TI *coli or AB *coli) OR (TI yeast* or AB yeast*) OR (TI fung*
or AB fung*) OR (TI VSL* or AB VSL*)
2. (TI Inflammatory bowel disease or AB Inflammatory bowel disease) OR (TI Ulcerative colitis or AB Ulcerative colitis) OR (TI UC or AB UC)
OR (TI IBD or AB IBD)
3. 1 and 2
Clinical trials.gov
1. Probiotics and inflammatory bowel disease (37)
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2. Probiotics and Ulcerative colitis (23)
3. Synbiotic and inflammatory bowel disease (3)
4. Synbiotic and Ulcerative colitis (1)
W H A T ' S   N E W
 
Date Event Description
29 November 2019 New citation required but conclusions
have not changed
There remains insufficient evidence for the use of probiotics
in maintaining remission in ulcerative colitis. Further research
against placebo is unlikely to provide useful data, and instead
comparisons to other therapies is proposed.
31 October 2019 New search has been performed We updated the searches in December 2017 and reran them in
October 2019; we added eight new studies to this update.
 
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 12, 2011
 
Date Event Description
8 May 2018 Amended ZIE, LK and PB were added to the author team
 
C O N T R I B U T I O N S   O F   A U T H O R S
Zipporah Iheozor-Ejiofor co-ordinated the review; extracted data and contacted authors; checked the quality of data extraction; analysed
and interpreted data; undertook and checked quality assessment; performed statistical analysis; checked the quality of the statistical
analysis; produced the first draT of the review; contributed to writing and editing the review; made an intellectual contribution to the
review; and approved the final review prior to submission.
Lakhbir Kaur performed screening of titles and abstracts and full-text articles, extracted data and contacted authors; contributed to writing
and editing the review; made an intellectual contribution to the review; and approved the final review prior to submission.
Morris Gordon performed screening of titles and abstracts and full-text articles, extracted data and contacted authors, analysed and
interpreted data; contributed to writing and editing the review; made an intellectual contribution to the review; contributed to previous
versions of the review; made final changes to the review, including the update search prior to publication and peer review changes; and
approved the final review prior to submission.
Patricia Baines contributed to writing and editing the review; made an intellectual contribution to the review; approved the final review
prior to submission
Vasiliki Sinopoulou made update changes to all sections of the review following peer review and repeated searches; and approved the
final review.
Anthony Akobeng initiated and conceptualised the review; contributed to previous versions of the review; and approved the final review
prior to submission.
D E C L A R A T I O N S   O F   I N T E R E S T
Zipporah Iheozor-Ejiofor: my employment at the University of Central Lancashire is funded by the National Institute for Health Research
(NIHR) UK and focuses on high priority Cochrane Reviews in Inflammatory Bowel Disease.
Lakhbir Kaur: none known
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Morris Gordon: received travel grants from various companies to attend scientific meetings in the last three years, including Biogaia,
Synergy, Tillots, Ferring and Allergan. None of these companies have had any involvement in the planning, completion, analysis or write up
of this or any other reviews. This review has been completed as part of a UK funded National Institute for Health Research (NIHR) Cochrane
Programme grant, with some time funded.
Patricia Baines: none known
Vasiliki Sinopoulou: none known
Anthony Akobeng: none known
S O U R C E S   O F   S U P P O R T
Internal sources
• School of Medicine, University of Central Lancashire, UK.
External sources
• National Institute for Health Research, UK.
This project was supported by the National institute for Health Research, via Cochrane Infrastructure and Cochrane Programme Grant
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